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ABSTRACT
EGFR SIGNALING FROM THE EARLY ENDOSOME
Julie Ann Gosney
June 6, 2018
The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase
that is an integral component of proliferative signaling. When activated by a
ligand at the plasma membrane, EGFR dimerizes with another ErbB family
receptor, leading to kinase domain activation and transphosphorylation of Cterminus tyrosine residues. These phosphotyrosines act as crucial regulators of
EGFR signaling as effector proteins dock to the receptor at these sites. The
receptor undergoes clathrin-mediated endocytosis into early endosomes, where
it can then be trafficked to a lysosome for degradation. However, the kinase
domain of EGFR retains its activity during trafficking, suggesting that EGFR can
continue to elicit signaling cascades after internalization. Unfortunately, there is
no consensus as to how EGFR spatial regulation affects its signaling or
interaction with downstream effectors. We hypothesize that EGFR localization in
early endosomes permits unique interactions with downstream effectors. In an
effort to identify proteins that uniquely associate with the internalized EGFR, we
have developed a strategy for isolating early endosomes and analyzed the
protein make-up of these compartments. HeLa cells were stimulated with and
without EGF, and the post-nuclear supernatant (PNS) was loaded onto a 17%
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Percoll gradient which separates endosomes based on density. The gradient was
fractionated, and fractions containing early endosomes were pooled and
immunoisolated with an EEA1 monoclonal antibody. The morphology of isolated
compartments was monitored using transmission electron microscopy.
Endosomes were also subjected to liquid chromatography/tandem mass
spectrometry (LC-MS/MS) for proteomic analysis. The isolation method
precipitates early endosome marker proteins, but not marker proteins specific to
other organelles. Electron microscopy revealed that the isolated vesicles are
intact and have an average diameter of 68.63 ± 26.74nm. More than 900 proteins
were isolated with the early endosome, and five proteins were detected in
endosomes in a ligand-dependent manner: EGFR, RUFY1, STOML2, PTPN23,
and CCDC51. RNAi was used to knock down RUFY1 and PTPN23 in HeLa cells
to monitor changes in the trafficking of EGFR. Knock-down studies revealed that
loss of PTPN23 leads to endocytic accumulation of EGFR and decreased
degradation of the ligand:receptor complex. Loss of RUFY1 resulted in a
significant increase in cell growth as well as a resistance to cell death.
We have developed a rapid and high-throughput isolation technique to
collect early endosomes from HeLa cells that can be analyzed by LC-MS/MS to
detect a distinct proteome. The purification protocol yields a highly enriched
population of early endosomes, as evidenced by immunoblot and LC-MS/MS
analyses. The isolated vesicles are also intact and exhibit morphology and size
distribution similar to early endosomes. These data provide evidence that
endocytic trafficking of the activated EGFR changes the protein composition and
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signaling potential of the early endosome.
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CHAPTER I
INTRODUCTION
A. Epidermal Growth Factor Receptor
The study of growth factors and their receptors is a rapidly growing field of
research that began in the 1960s when Stanley Cohen and Rita Levi-Montalcini
discovered the first growth factors: Nerve Growth Factor (NGF) and Epidermal
Growth Factor (EGF) [1, 2]. NGF and EGF are small proteins that stimulate the
growth of nerve and epithelial cells, respectively. Before the discovery of growth
factors, scientists knew that cells could signal for growth and proliferation,
particularly during development—but they didn’t understand how this
phenomenon occurred [1]. The identification of NGF and EGF was pivotal, as
these proteins could now be studied directly in order to elucidate their functions
in cellular and organ physiology [3]. These discoveries were a major scientific
breakthrough that earned Cohen and Levi-Montalcini a shared Nobel Prize in
1986 [4].
Upon Levi-Montalcini’s discovery of NGF, she and Cohen worked
diligently to understand its function. Because NGF was discovered in the
submaxillary glands of mice, they continued using these extracts to study its
effects on neuronal growth [5]. However, injecting mouse salivary gland extracts
into newborn pups ended up yielding other, unexpected phenotypes. Cohen
noted that these new changes were not due to the induction of nerve growth, but
1

due to changes in epithelial tissues [2]. During Cohen’s original experiments
characterizing his novel epithelial tissue-specific growth factor, he referred to the
protein as the “tooth-lid factor” [2]. While the title was only temporary until he
coined the name EGF, the “tooth-lid factor” was so named because it directly
described the effects he saw in mice injected with EGF: it increased the rates of
tooth growth and eyelid opening in newborn pups [2].
The discovery and characterization of growth factors led to another
essential discovery—growth factor receptors. Once Cohen had discovered EGF,
he immediately began working to isolate and identify its receptor. In 1982 Cohen
successfully isolated and characterized EGF’s cognate receptor from A431 cells
and mouse livers [3, 6]. In this work, the receptor was identified as a 170kDa
glycoprotein with intrinsic tyrosine kinase activity. Over the next three decades,
the EGF-receptor was studied extensively, leading to the most current
understandings of the signaling, trafficking, regulation, and physiologic
implications of this protein.
The epidermal growth factor receptor (EGFR) is a membrane spanning
receptor tyrosine kinase (RTK) that is an integral component of proliferative
signaling. Part of the ErbB family of receptors, EGFR is also referred to as ErbB1
or Her1 (human ErbB1). The other ErbB family members include ErbB2 or Her2,
ErbB3, and ErbB4. Structurally, EGFR and the ErbB receptors are made up of
three domains: 1) the extracellular ligand binding domain, 2) the transmembrane
alpha helices, and 3) the intracellular domain which contains the kinase domain
and multiple tyrosine residues on the C-terminus (Figure 1.1). The extracellular
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domain contains two ligand-binding regions that alternate with two cysteine-rich
regions. Binding of one of EGFR’s seven endogenous ligands—epidermal growth
factor (EGF), heparin-binding EGF-like growth factor (HBE), epiregulin (EPR),
epigen, transforming growth factor alpha (TGFα), amphiregulin (AR), and
betacellulin (BTC)—to the extracellular region induces a conformational change
in which the ligand binding regions directly interact with the ligand [7]. This
structural change exposes the two cysteine-rich domains, allowing the receptor
to associate with the exposed cysteine-rich domains of another ligand-bound
EGFR or ErbB family RTK monomer to form a dimer [7].
The binding of two ligand-bound receptors causes the formation of a
dimer, which is required for receptor activation [8]. The dimer pair interaction
structurally induces the activation of the kinase domains. The kinase domain of
one receptor then phosphorylates the C-terminal tyrosine residues of its dimer
partner (transphosphorylation) [8]. The cytosolic phosphorylated tyrosine
residues of the EGFR serve as docking sites for effector molecules that contain
phosphotyrosine binding (PTB) or src homology 2 (SH2) domains [9]. Proteins
that dock to the phosphorylated tyrosine residues of an activated EGFR will
recruit and/or activate other proteins, thus inducing a signaling cascade. For
example, at the plasma membrane, an activated EGFR dimer will recruit the
scaffolding proteins Shc and Grb2 to bind to phosphotyrosines and the EGFR
kinase domains phosphorylate these proteins [9]. Activation of Grb2 leads to the
recruitment of SOS and induction of the Ras-ERK pathway which is known to
activate cell proliferation [9]. Activation of Shc leads to induction of the JNK
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Figure 1.1 Epidermal Growth Factor Receptor structure. When unbound by a
ligand, the receptor is often found in a “closed” conformation in which the
cysteine-rich regions of the extracellular region interact. When a ligand is
introduced it binds to the two ligand binding domains and a conformational
change occurs, exposing a cysteine-rich region which can then interact with an
exposed cysteine-rich region of another ligand-bound ErbB family receptor.
Red=inactive kinase domain; green=active kinase domain; orange=ligand binding
domains; blue=cysteine-rich domains.
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pathway which is also known to be involved in the induction of cell proliferation
via the activation of nuclear transcription factors [9].

B. EGFR Function
EGFR signaling plays critical roles in cell proliferation, migration,
differentiation, wound healing, development, and tissue homeostasis. Growth
factors are mitogens, and the EGFR is an important mitogenic signal transducer.
In fact, the EGFR is an essential component of cellular physiology and is critical
for proper tissue development. In 1995, Miettinen et al. produced a line of EGFR
knockout mice to determine the physiologic importance of the receptor in
development [10]. They found that their line of knockout (-/-) pups only survived
for eight days after birth. The mice also had significant developmental
impairments in multiple epithelial tissues and organs including the lungs, skin,
and gastrointestinal tract [10]. In 1999 Miettinen also documented that EGFR (-/-)
pups have compromised craniofacial development (Figure 1.2) [11]. EGFR is
clearly a crucial component for normal tissue development and homeostasis
throughout the body.
While the absence or reduction of EGFR signaling unquestionably causes
severe developmental impairments, excessive EGFR signaling also has
detrimental effects. It has been well documented that the receptor is often
overexpressed and/or over-activated in many different cancer types, including
non-small cell lung cancer, breast, pancreatic, cervical, head and neck, and
colorectal cancer among others [12-17]. Glioblastoma multiforme (GBM) was

5

Figure 1.2 The effects of EGFR knockout on craniofacial development in
mice. a) A wild-type newborn mouse has a round snout, whereas b) an EGFR (/-) mouse has a narrower snout. c) The nostrils of wild-type mice are open
(arrow), d) but are often closed or narrow (arrow) in EGFR (-/-) mice. e) A wildtype mouse at four months of age has long whiskers and a well-shaped snout,
whereas f,g) EGFR (-/-) mice have smaller lower jaws (arrows), deformed eyes,
and short, curly whiskers. (Used with permission [license # 4332530233617] from
Nature Genetics (1999), 22, 69-73)
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the first cancer associated with mutated EGFRs. Approximately 70% of GBMs
express a constitutively active truncation mutant (EGFRvIII) with deletions in
exons 2-7 of the extracellular domain [18]. The loss of the extracellular domain
allows spontaneous, ligand-independent receptor dimerization and activation.
The EGFRvIII mutation is also overexpressed due to gene amplification. In
addition, constitutively active mutations of the receptor are frequently associated
with non-small cell lung cancer (NSCLC), one of the most common and lethal
forms of lung cancer with a 5-year survival rate of only 17% [19, 20].
Approximately 50% of NSCLC patients who identify as “never smokers” have
EGFR exon 19 deletions, exon 20 insertions, and the amino acid point mutation
L858R [21]. All three of these mutations change the kinase domain of the
receptor to favor an active state to induce constitutive kinase activity and
signaling of EGFR.
In contrast to activating mutations, other cancers seem to be driven by
EGFR overexpression (e.g. colorectal, breast, pancreatic, and head and neck).
There are multiple mechanisms by which EGFR levels may be enhanced,
including increased gene amplification, mRNA production, or protein translation.
In breast carcinomas, EGFR gene amplification occurs in 6% of tumors, and 91%
of these tumors also exhibit EGFR protein overexpression [13]. In approximately
20% of high grade cervical intraepithelial neoplasia (CIN) and invasive cervical
carcinomas, EGFR gene amplification has also been linked to EGFR
overexpression and poor prognosis [15]. However, approximately 65% of
pancreatic ductal adenocarcinomas (PDAC) exhibit overexpression of EGFR, but
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without EGFR-specific gene amplification [14]. For PDAC, these changes in
protein levels are likely due to overexpression of other ErbB family members
such as ErbB2 [14] .
There are currently several FDA-approved anti-EGFR cancer therapies on
the market. These drugs are generally split up into two classes—monoclonal
antibodies and kinase inhibitors. The monoclonal antibodies (e.g. Cetuximab)
target the extracellular portion of the receptor and block the interaction of the
receptor with extracellular activating ligands. Cetuximab is approved for the
treatment of cancers that express high levels of EGFR, including colorectal and
head and neck cancers [22]. Tyrosine kinase inhibitors (TKIs) (e.g. Erlotinib) are
small molecules that enter the cell and bind (reversibly or irreversibly) to the
kinase domain of the receptor, blocking effector activation and downstream
signaling cascades. Erlotinib is approved for use in NSCLC patients whose
cancers express EGFR kinase activating mutations, including exon 19 deletion
and exon 21 (L858R) substitution mutations [23]. While these drugs tend to be
very effective initially for patients whose cancers express over-activated
receptors, eventually all of these patients will develop resistance to the drugs
[24]. The exact mechanism by which this resistance occurs is unclear, although
several studies suggest that the inhibited receptors can form heterodimers with
other ErbB family members and even the insulin-like growth factor type-1
receptor (IGF-1R), another RTK with mitogenic effects [25]. In addition to drug
resistance, patients also tend to develop adverse side-effects to anti-EGFR
therapies. While some rare adverse reactions have occurred, the most common
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side-effects are skin lesions and conjunctivitis [26, 27].
Although significant advances in cell biology research have led to the
development of targeted therapeutics such as the anti-EGFR cancer drugs, these
therapies provide an overall survival increase of only a few months for these
subsets of cancer patients [28]. This lack of improvement, coupled with the
resistance that develops from these treatments, reveals that there is an
enormous gap in the field’s understanding of mitogenic signaling. If more robust
cancer treatments are to be developed, it is essential that the mechanisms
driving the proliferation and metastasis of these cells are elucidated. Because
targeting the EGFR directly has yielded only a minimal benefit to patient
outcomes, it would be prudent to find more specific targets within the receptor’s
signaling pathways.
Unfortunately, there are still many facets to EGFR signaling that have yet
to be elucidated. One such question that could play an important role in
understanding EGFR downstream signaling is: how does the spatial regulation of
the receptor affect its signaling? This is the primary question we seek to answer
in this work.

C. Endocytosis
The major mechanism through which the EGFR is regulated is the
endocytic pathway (Figure 1.3). Once the activated dimer is formed it migrates to
a clathrin-rich region of the plasma membrane where it invaginates and pinches
off into a clathrin-coated vesicle. The clathrin is then shed, and this intermediate
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Figure 1.3 Endocytic trafficking of the EGFR. The EGFR undergoes liganddependent, clathrin-mediated endocytosis. Early endosomes either mature into
late endosomes where their contents are transported to lysosomes for
degradation, or the receptor can be trafficked back to the plasma membrane via
a recycling endosome. The increasing acidity of these compartments induces
dissociation of the ligand:receptor complex. The EGFR can continue to elicit
signaling cascades from the early endosome. Red=ligand, green=active kinase
domain, orange=clathrin.
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vesicle fuses with an early endosome [29]. The early endosome, sometimes
referred to as the signaling or sorting endosome, is the epicenter of endocytic
trafficking. This organelle is responsible for determining the fate of its contents,
depending on several factors including what ligand is bound and with which ErbB
family member the EGFR is dimerized. The early endosome can send proteins
back to the plasma membrane (recycling) [30], or sequester cargo to be sent to
and degraded in a lysosome [31]. It has been reported that endocytosis can also
transport EGFR to the endoplasmic reticulum and the nucleus [32, 33]. Over time
early endosomes increase in acidity and “mature” into late endosomes [34]. The
late endosomes will fuse with a lysosome, where the receptor is degraded and
thus down-regulated. It is important to note that while in the early endosome the
kinase domain of the receptor remains exposed to the cytosol, allowing the
receptor to continue interacting with other proteins and downstream effectors
[35].
Until the 1990s, EGFR spatial regulation by the endocytic pathway was
viewed primarily as a mechanism for downregulating receptor expression after
activation. Chen et al. discovered in 1989 that an 18 amino acid sequence of the
EGFR C-terminus is required for both kinase activation and internalization/
downregulation of the receptor [36]. Shortly thereafter in 1990, Wells et al.
discovered that mutated EGFRs that are endocytosis-deficient enhance cell
transformation [8]. They concluded from this study that without endocytosis, the
receptor cannot be degraded and thus increases ligand-dependent cell
transformation. As such, endocytosis was viewed as a negative regulator of
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EGFR expression. However, in 1994 Bergeron’s group discovered that certain
EGFR scaffolding proteins involved in Ras signaling (i.e. Shc, Grb2, and mSOS)
retain their association with active EGFR when it is internalized [30]. Further, in
1996, Vieira et al. created an endocytosis-defective cell line to study the changes
in EGFR downstream effector activation after EGF treatment. They found that
blocking EGFR endocytosis enhanced PLCγ and Shc phosphorylation, but
decreased ERK1/2, EGFR, & PI3K phosphorylation [31]. These works, among
others, pushed the field of EGFR trafficking toward a new line of thinking:
endocytosis can positively and negatively affect receptor:effector communication.
However, there is currently no consensus on how these changes occur, or how
they contribute to EGFR signaling and overall cellular physiology.
It has been well established that the endocytic pathway is important in the
spatial as well as temporal regulation of the EGFR. The receptor is regulated
temporally by the amount of time it takes to traverse the entire endocytic
pathway, and how long the receptor is sequestered at each point of the pathway.
About 10% of a cell’s inactive EGFRs are constitutively recycled into early
endosomes and back to the plasma membrane [37]. It has also been shown that
different ligands induce varied endocytic responses. For example, it is known that
TGFα triggers rapid recycling of the receptors, while EGF triggers the receptor to
be maintained in early endosomes, leading to its eventual degradation and
downregulation [38].
One explanation for these distinct differences in ligand:receptor trafficking
amongst ligands is their affinity for the receptor. EGF is known to have a
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relatively high affinity for binding EGFR of 0.42nM [39], and thus does not
dissociate from the receptor in the acidic environment of early endosomes (pH
6). However, TGFα has a slightly lower affinity for the receptor at 11.9nM [39],
causing the ligand:receptor complex to dissociate in early endosomes, permitting
receptor recycling to the plasma membrane [38]. Though both ligands are
considered to have “high” affinities for EGFR [40], they do not have the same
effects on receptor trafficking. Conversely, the work of Moriai et al. suggests that
EGF and TGFα have similar affinities for EGFR, and that certain mutations in the
ligand binding domain of some EGFRs may contribute to the different binding
affinities and downstream signaling effects of ligands [41].
The endocytic pathway is a complex and dynamic system made up of
various organelles [42]. Endocytosis is a fundamental cellular process in which
extracellular nutrients and portions of the plasma membrane are internalized into
the cell [42]. A section of plasma membrane will invaginate and pinch off to form
an intracellular vesicle [42]. These preliminary vesicles are typically formed with
the assistance of several adaptor and scaffolding proteins that are found near or
on the plasma membrane [43]. For example, clathrin-mediated endocytosis
(CME) requires the cytosolic protein clathrin, which forms a triskelion coat around
the portion of plasma membrane that is to be internalized [43]. This process also
requires another protein called dynamin that plays a critical role in the scission of
the new vesicle from the plasma membrane [43]. CME is also referred to as
receptor-mediated endocytosis, as it occurs when a plasma-membrane receptor
is bound and activated by an extracellular ligand, triggering its internalization
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(e.g. EGF binding to EGFR) [43]. During CME, after the new vesicle is created
the clathrin coat is shed. This intermediate vesicle is then trafficked to and fused
with an endosome, of which there are several types [43]. The destination of each
vesicle is specific to its cargo and has a direct impact on the fate of that cargo.
This process is highly regulated by actin filaments and microtubules, adaptor
proteins, and GTPases such as the RAB proteins [43]. The RAB family of
proteins are Ras-like GTPases that play an essential role in the endocytic
pathway by recruiting effectors that induce the formation and motility of
endosomes [44]. There are more than 60 different RAB proteins, and each one is
generally specific to a distinct cellular compartment [45]. In 1990, Chavrier and
Zerial determined that RAB5 is specific to the plasma membrane and early
endosomes, and RAB7 localizes to late endosomes [46]. RAB11 is another
member of the RAB family that is specifically localized to recycling endosomes
[47]. These three RAB proteins are the major players involved in generating the
vesicles involved in the early phases of endocytosis (i.e. early, late, and recycling
endosomes).
Clathrin-mediated endocytosis is the primary pathway by which activated
EGFR enters early endosomes when stimulated with low, endogenous
concentrations of ligand (i.e. ~1ng/mL or 0.16nM EGF) [48]. However, there are
other types of endocytosis that utilize adapter proteins similar to clathrin. For
example, caveolae are small pits in the plasma membrane made up of lipid rafts
and the protein caveolin [49]. Caveolae are also involved in the endocytosis of
plasma membrane and extracellular ligands and nutrients. This process is similar
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to CME, as it also requires dynamin for the scission and formation of vesicles
[43]. It also differs from CME in that caveolae cargo can either be delivered to
early endosomes or to caveosomes [49]. Caveosomes are pH-neutral
intracellular vesicles that strictly contain cargo transported from caveolae, and
they do not contain early endosome proteins, although their function is similar to
early endosomes [49]. There are other routes of endocytosis that do not involve
clathrin or caveolae, which are collectively termed clathrin- and caveolaeindependent endocytosis [43]. The major routes of EGFR-endocytosis are CME
at low ligand concentrations, and caveolae-mediated endocytosis (CavME) at
high ligand concentrations (i.e. >10ng/mL or >1.6nM EGF) [48].
Whether via CME or CavME, most endocytic cargo will be transported into
early endosomes. Early endosomes are so named because they are found in the
cytosol near the plasma membrane, and they are the first major constituent
within the endocytic pathway. These organelles are considered to be slightly
acidic, with a pH of ~6.0 and a density of 1.035-1.042g/mL [34, 50]. Early
endosomes are the first pit-stop in the pathway, and the sequestration of
receptors here is critical to their ultimate fate.
There are two distinct populations of early endosomes: dynamic and
static. In 2006 Lakadamyali and Rust discovered and characterized these types
of endosomes by their mobility and maturation kinetics [51]. To do this, RAB5
and RAB7 were fluorescently tagged and the association of these proteins with
various ligands that undergo CME were tracked using live cell imaging. They
found that the static population of early endosomes are the most abundant, and
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they mature very slowly. The dynamic early endosomes are strongly associated
with microtubules and mature rapidly into late endosomes. Remarkably,
ligand:receptor complexes that are normally degraded via the endocytic pathway,
such as EGF:EGFR and low density lipoprotein and its cognate receptor
(LDL:LDLR), were preferentially trafficked into the dynamic population of early
endosomes. On the other hand, complexes that are typically recycled, such as
transferrin and its receptor (Tfn:TfnR), were trafficked non-specifically to both
populations of early endosomes [51]. This study provides further evidence that
the endocytic pathway is highly regulated and the fate of every cargo that enters
is tightly monitored.
As evidenced by the fates of the EGFR and TfnR, early endosomal
contents can be segregated into various legs of the endocytic pathway. Certain
proteins that are marked for recycling back to the plasma membrane can be sent
directly to the cell membrane by an intermediate vesicle, or trafficked to a larger
specialized vesicle called the recycling endosome [42]. Contents that are not
recycled will remain sequestered in early endosomes. The organelles that
comprise the endocytic pathway possess proton pumps on their membranes that
maintain their luminal pH [34, 52]. However, over time these pumps will increase
the acidity of early endosomes. This is a crucial step in the “maturation” process
of an early endosome into a late endosome [53].
Late endosomes are also termed “multivesicular bodies” or MVBs, and
have an acidic pH of ~5.3 and a density of 1.048-1.070g/mL [34, 50]. The name
MVBs comes from the presence of intraluminal vesicles that are created within
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the organelle [54]. These are small, membrane-bound vesicles that are
internalized from the outer membrane of the late endosome itself, which is also
referred to as the “limiting membrane” [54]. Receptors and other cargo found in
the late endosome that are to be degraded are marked as such by entering into
these intraluminal vesicles [54]. There are specific protein complexes called
ESCRTs (endosomal sorting complex required for transport) that are required for
the transport of cargo from the limiting membrane into intraluminal vesicles of
late endosomes [55]. ESCRT complexes specifically interact with ubiquitinated
cargo within the late endosome, as ubiquitination marks proteins for degradation
[55]. Once a cargo is sequestered into an intraluminal vesicle, it is destined to be
transported to a lysosome where it will be degraded. The late endosome will
temporarily fuse with a lysosome and transfer its contents (intraluminal vesicles)
to the lysosome [56].
Lysosomes are separate organelles that have a pH of ~5.0 and a density
of between 1.070-1.110g/mL [34, 50]. The sole purpose of a lysosome is to
degrade proteins, as they are filled with acid hydrolases to break down cargo
[56]. This compartment is the final stop in the endocytosis of cargo that is marked
for degradation (i.e. ubiquitinated). This degradation process is essential for the
down-regulation of a multitude of cellular components, including signaling
receptors like EGFR [56].

D. Significance and Statement of Specific Aims
The EGFR is an important endogenous RTK that is overexpressed and/or

17

hyperactivated in multiple cancer types (e.g. breast, colon, lung, pancreatic, etc.).
While there are currently several FDA-approved therapies that target EGFR in
these cancers, in many cases these cancers either do not respond or quickly
develop resistance [24]. Further, patients who do benefit from anti-EGFR
therapies only gain a few additional months of life. As a result, it is clear that
targeting EGFR directly is not the most effective way to mitigate its signaling in
cancer. We propose that better alternative approaches for disrupting EGFR
signaling will come from examining the molecular mechanisms that regulate
EGFR activity, i.e. endocytosis. It has been well understood for decades that
endocytic spatial regulation plays a major role in receptor expression and
downregulation. However, in recent years it has been discovered that receptor
endocytosis also plays a role in downstream effector activity. How this process
specifically affects overall EGFR signaling is not completely understood, and it
could be a useful target for disrupting hyperactivated signaling.
My research goal was to understand how endocytosis affects EGFR signal
transduction, and to use this information to discover new targets for cancer
therapies. The objective of this work was to determine the effects of EGFR
spatial regulation on its signaling. My central hypothesis was that the spatial
regulation of EGFR permits specific effector interactions that directly influence
downstream signaling. This hypothesis was based on the most recent data in the
field which suggest that endocytic trafficking of EGFR induces changes in
downstream effector activation. For example, blocking EGFR endocytosis
decreases the activity of certain effectors, such as ERK1/2 and PI3K [31]. More
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recently, the work of Galperin and Sorkin suggests that MEK enters endosomes
and acts as a negative regulator of MAPK signaling upon EGF stimulation [57].
While the spatial regulation of EGFR clearly plays a role in effector activity, there
is controversy within the field surrounding endosome-specific effectors and their
implications on overall signal transduction. The rationale for this work was that a
comprehensive understanding of the effects of EGFR:effector interactions within
endosomes will be a means for discovering many new drug targets for altering
EGFR mitogenic signaling. Considering the current outcomes for EGFR targeting
in cancer, this information is critical for the discovery of more effective
treatments.
My hypothesis was tested with the following aims:
Aim 1: Identify and characterize key effectors within early endosomes.
Aim 1a. Develop a non-invasive strategy to purify early endosomes.
In order to achieve a global, comprehensive picture of the early endosome
effector population, we isolated intact early endosomes from cultured cell lines.
Aim 1b. Characterize effector activation in early endosomes.
We used mass spectrometry to characterize early endosome-specific effectors
following treatment with and without EGF. The goal of this sub-aim was to
determine which effectors are constitutively present in the early endosome, and
which effectors are selectively localized to early endosomes by EGFR membrane
trafficking.
Aim 2: Determine the physiologic effects of endocytic spatial regulation on
EGFR signaling.
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Based on my hypothesis, we determined how the spatial regulation of EGFR
influences cell physiology using cultured cell lines. We used assays to measure
cell growth and viability to determine how these processes are affected by the
absence of specific downstream effectors of EGFR.
The aim of this work was to provide a systematic and comprehensive
approach to understanding how EGFR signaling is regulated, which will lead to
discovering new ways to attenuate it more effectively. The work proposed in Aim
1 gave us a more complete picture of early endosome-specific effectors. More
specifically, we discovered that the proteins RUFY1, PTPN23, STOML2, and
CCDC51 associate with early endosomes in an EGF-dependent manner. The
work proposed in Aim 2 helped us identify what roles the proteins discovered in
Aim 1 play in the endocytic trafficking of EGFR. This work has been published in
the Journal of Biological Chemistry. Additional work has been done to
characterize how the loss of RUFY1 and PTPN23 affects cell number and
viability. These results are discussed at length in Chapter IV of this dissertation.
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CHAPTER II
MATERIALS AND METHODS
A.

Cell Lines—HeLa cells were acquired from American Type Culture

Collection (ATCC). Cells were cultured at 37°C in 5% CO2 and maintained in
Dulbecco’s Modified Eagle Medium (DMEM, Gibco) supplemented with 5% Fetal
Bovine Serum (FBS, Invitrogen), 100 units/mL streptomycin, 100 units/mL
penicillin, and 2mM glutamine [58].
B.

Post-Nuclear Supernatant Preparation—Cells were grown to confluence in

15cm dishes, serum starved for 2 hours at 37°C, then incubated with or without
10ng/mL EGF ligand (ProSpec, #cyt-217-a) for 15 minutes immediately prior to
harvest. Cell lysates were prepared by washing twice with room temperature
(RT) PBS and equilibrating to 4°C on ice, followed by equilibrating in ice-cold
lysis buffer (TES-10mM triethanolamine, 1mM EDTA, 0.25M sucrose pH 7.2).
Cells were incubated on ice with TES buffer (supplemented with 2mM PMSF,
1mM Na3VO4, 10μM pepstatin, and 1μM aprotinin) until cells began to swell, but
before bursting (approximately 5 minutes), and scraped with a rubber policeman.
The collected cells were pipetted up and down 40 times with a P1000 pipetman
and centrifuged at 200 x g for 10 minutes at 4°C in a tabletop centrifuge to create
a post-nuclear supernatant (PNS) which was subsequently collected. The pellet
was resuspended in TES buffer and centrifuged a second time at 200 x g for 10
minutes at 4°C. Supernatants were pooled to yield a final PNS [50].
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C.

Percoll Gradient Fractionation−Twenty-four hours prior to experimentation,

stock Percoll (GE Healthcare) was equilibrated with 2.5M sucrose at a ratio of
9:1. The 90% Percoll/0.25M sucrose solution was stored at 4°C until use.
Samples were prepared as indicated (by PNS preparation via either osmotic lysis
or mechanical lysis, or by sucrose gradient fractionation), and each sample was
mixed with the 90% Percoll solution (final concentration 17% Percoll) and TES to
a total volume of 11.5mL. Buffers were supplemented with 2mM PMSF, 1mM
Na3VO4, 10μM pepstatin, and 1μM aprotinin before use. PNS/Percoll/Buffer
mixtures were pipetted into 16mm x 67mm OptiSeal™ polypropylene tubes
(Beckman Coulter) and loaded into a pre-chilled VTi65.1 vertical rotor. Density
beads (with known densities in 17% Percoll/250mM sucrose) (GE Healthcare)
were loaded into a separate tube containing 17% isotonic Percoll in buffer and
mixed. Samples were spun in a Beckman Coulter Optima L-100 XP
Ultracentrifuge at 50,000 x g for 25 minutes with max acceleration and brake.
Samples were then fractionated from the bottom of the centrifuge tube in 10-drop
aliquots (~330μL) into pre-chilled Eppendorf tubes (~30 fractions per gradient)
using a peristaltic pump and a glass pipet at 4°C [50]. For experiments where
fractions were subjected to affinity purification, the fractions in which EEA1
protein concentration peaked were pooled together (~6 fractions per condition,
~2mL total) and mixed by inverting and gently pipetting up and down. For
experiments where fractions were not pooled but analyzed directly via
immunoblot, each fraction was diluted in 6X SDS sample buffer containing 10%
β-mercaptoethanol (βME), boiled at 100°C for 3 minutes, and centrifuged at
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21,000 x g to pellet Percoll. The tube containing density beads was imaged and
Rf values were calculated based on bead migration in the gradient.
D.

Affinity Purification of Early Endosomes—Approximately 0.44μg of EEA1

monoclonal antibody (Cell Signaling, #3288) was pre-conjugated to ~2mL of
pooled EEA1 peak fractions (Rf of ~0.25-0.10) from Percoll gradient samples
overnight at 4°C with rotation. Protein G Dynabeads (Invitrogen) were washed
three times in PBS before use and ~4.0 x 107 Dynabeads were incubated with
each antibody-conjugated sample and rotated at 4°C for 1 hour. Magnetic beads
were isolated and the first supernatant (pass through) was collected. The beads
were then washed three times in ice-cold PBS and eluted in 6X SDS buffer
containing 10% βME and boiled at 100°C for 3 minutes. Remaining samples
collected were diluted in 6X SDS buffer with 10% βME and boiled. Any samples
containing Percoll were centrifuged at 21,000 x g to pellet Percoll.
E.

Immunoblotting—Samples were loaded as a percentage of total sample

volume, resolved by SDS-PAGE, and transferred to nitrocellulose. Membranes
were probed with the following antibodies according to manufacturer’s directions:
EGFR (Santa Cruz, #sc-03), TfnR (BD Biosciences, #612124), LAMP2
(University of Iowa Hybridoma Bank, #H4B4), EEA1 (BD Biosciences, #610456),
Na/K-ATPase (Sigma, #A276-only used where indicated), Na/K-ATPase (Cell
Signaling, #3010), Calnexin (Assay Designs, #SPA-850), pY1068 (Cell Signaling,
#2236), PTPN23 (Proteintech, #A304-883A), RUFY1 (ThermoFisher Scientific,
#PA5-31400), STOML2 (Abcam, #ab191884), α-tubulin (Sigma-Aldrich, #T6199),
and PARP (Cell Signaling, #9542). Following incubation with the appropriate
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horseradish peroxidase conjugated secondary antibody (anti-mouse or antirabbit, Thermo Fisher-Pierce), immunoreactive proteins were subjected to
Enhanced Chemiluminescence and visualized using a Fotodyne imaging system.
Western blots were quantified using Image J software.
F.

Indirect Immunofluorescence—HeLa cells were grown to confluency on

NaOH treated, sterile 12mm round glass coverslips. Serum starved cells were
incubated with EGF (ProSpec, #cyt-217-a) ligand for the indicated amount of
time. Cells were stimulated with 10ng/mL fluorescent Alexa-647-EGF ligand
(Invitrogen) for 10 min and pulse-chased following previously described methods
[59]. After EGF stimulation, cells were subjected to indirect immunofluorescence
as described previously [60] using EGFR (Ab-1, EMD Millipore, #GR01), EEA1
(BD Biosciences, #610456), PTPN23 (Proteintech, #A304-883A), RUFY1
(ThermoFisher Scientific, #PA5-31400), and STOML2 (Abcam, #ab191884)
primary antibodies prepared by manufacturer recommended dilutions.
Immunoreactive proteins were visualized using goat anti-rabbit Alexa488- and
goat anti-mouse Alexa568-labeled secondary antibodies (Life Technologies),
respectively. Coverslips were mounted onto glass slides with Prolong Gold
Antifade (Life Technologies) [60]. Slides were cured in the dark overnight before
imaging. Images were taken in the middle plane of the cells using a 60X oil
immersion objective lens on a Nikon A1R confocal microscope.
G.

Colocalization Analysis—Colocalization of EGF or EGFR with EEA1 was

quantified as described by Lopez-Alcala et al. (50) and Vanlandingham et al.
[59]. Briefly, analysis was carried out using ImageJ Software and the
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Colocalization plug-in (Pierre Bourdoncle, Institut Jacques Monod, Service
Imagerie, Paris) to generate a binary image of colocalized pixels from two
separate channels. ImageJ was used to automate channel thresholding, and
colocalization was established for pixels whose intensities were higher than
threshold and for which the ratio of intensity was greater than 50%. The data
were plotted as the ratio of the integrated intensity from the two images. All data
represent the average of three independent experiments, with a total of ~300
cells measured per experiment.
H.

Coomassie Staining—Immunoprecipitated early endosomes were

resolved on a 12% SDS-PAGE. The gel was rinsed once in ddH2O and covered
with Coomassie (50% MeOH, 0.05% Coomassie Brilliant Blue R [Sigma], 10%
acetic acid, 40% ddH2O) and microwaved for 5 seconds. The gel was incubated
with Coomassie at RT with gentle rocking for 15 minutes. The Coomassie was
removed and the gel was rinsed twice in ddH2O. The gel was then covered in
destain solution (7% glacial acetic acid, 5% MeOH, 88% ddH2O) and incubated
overnight at RT with gentle rocking. The gel was rinsed in ddH2O, imaged using
a Fotodyne imaging system, and stored in 7% acetic acid/ddH2O at 4°C.
I.

In-Gel Protein Digestion—This protocol is modified from Jensen et al. [61].

A Coomassie stained SDS-PAGE gel was cut into 1mm3 plugs and incubated in
100mM triethylammonium bicarbonate (TEA-BC, Sigma) at RT for 15 minutes.
Acetonitrile (ACN) was added to the TEA-BC solution and the gel plugs were
incubated at RT for 15 minutes with gentle vortexing. The solvent was removed
and the washing process was repeated until the Coomassie blue stain was no
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longer visible. Solvent was removed and the gel plugs were dried in a SpeedVac
for 5 minutes. The dried plugs were incubated in dithiothreitol (DTT) (20mM DTT
[BioRad],100mM TEA-BC) at 56°C for 45 minutes, followed by iodoacetamide
(55mM iodoacetamide [Sigma], 100mM TEA-BC) at RT for 30 minutes protected
from light. Iodoacetamide was removed and gels were washed in 50mM TEA-BC
at RT for 15 minutes, followed by the addition of ACN for 15 minutes at RT with
gentle vortexing. The gel plugs were again dried for 5 minutes in a SpeedVac,
and incubated in digestion buffer (20ng/μL modified Trypsin [Promega] in 50mM
TEA-BC) for approximately 10 minutes until the gel plugs swelled. After swelling,
50mM TEA-BC was added to the plugs, followed by 37°C overnight incubation in
a shaker. Digestion supernatants from the upper and lower half of the gel were
combined for each sample.
J.

Extraction of Peptides—This protocol is modified from Shevchenko, et al.

[62]. LC-MS grade water was added to the digested gel plugs to give a final
concentration of 25mM TEA-BC. Two volumes of 1:2 5% v/v formic
acid:acetonitrile was added and incubated at RT for 15 minutes in a shaker
(100rpm in a C25 Incubator Shaker [New Brunswick Scientific]). Liquid
surrounding the gel pieces was transferred to a clean microtube and dissolved in
Chromatography Buffer A (2% v/v acetonitrile/0.1% v/v formic acid). The
dissolved sample was filtered through a 0.45μm regenerated cellulose syringe
filter (Thermo #F2504-7) to remove any remaining gel material. Resolubilized gel
band digests were desalted and concentrated using C18 PROTO™, 300 Å Ultra
MicroSpin Column (The Nest Group, Inc., Southborough, MA, USA). Samples
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were cooled to -80°C, dried using a SpeedVac, and redissolved in
Chromatography Buffer A. Sample absorbance was read at 205nm using a
NanoDrop 2000 spectrophotometer to determine peptide concentration. Sample
volumes were adjusted in Buffer A to normalize peptide concentrations to
0.1μg/μL.
K.

Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)—Gel

band digests (0.5µg) were separated on 12cm of Aeris Peptide XB-C18, 3.6μm,
100Å material (Phenomenex, Torrance, CA, USA) packed into a 360µm OD x
100µm ID fused silica tip that was pulled using a Model P-2000 Micropipette
Puller (Sutter Instrument Co., Novato, CA, USA). Peptides were eluted from the
column using an EASY n-LC UHPLC system (Thermo Fisher Scientific, Waltham,
MA, USA) in an 80 minute linear gradient using Buffer A and Buffer B (80% v/v
acetonitrile/0.1% v/v formic acid) as mobile phases (from 0% Buffer B to 50%
Buffer B). The samples were then separated by a 5 minute linear gradient from
50% Buffer B to 95% Buffer B, followed by a 5 minute wash in 95% Buffer B. The
sample was introduced into the LTQ-Orbitrap Elite (ThermoElectron) mass
spectrometer by nanoelectrospray using a Nanospray Flex source
(ThermoElectron). The ion transfer capillary temperature was set to 225°C and
the spray voltage was set to 1.6kV. An Nth Order Double Play was created in
Xcalibur v2.2. Scan event one of the method obtained an FTMS MS1 scan
(normal mass range; 240,000 resolution, full scan type, positive polarity, profile
data type) for the range 300-2000m/z. Scan event two obtained ITMS MS2 scans
(normal mass range, rapid scan rate, centroid data type) on up to twenty peaks
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that had a minimum signal threshold of 5,000 counts from scan event one. The
lock mass option was enabled (0% lock mass abundance) using the
371.101236m/z polysiloxane peak as an internal calibrant. Proteome Discoverer
v1.4.1.14 (Thermo Fisher Scientific) was used to analyze the mass spectrometer
data. MS2 scan data were extracted from the Xcalibur RAW file, CID MS2 scans
were searched in Mascot v2.5.1 (Matrix Science, Inc., Boston, MA, USA) and
SequestHT, and results were collected in a single file. The protein database
UniprotKB Homo sapiens version 3/9/2016 reference proteome canonical and
isoform sequences, with cRAP database (thegpm.org) version 1/1/2012
appended to it, were used in the Mascot and SequestHT searches. The resulting
files from Proteome Discoverer were loaded into Scaffold Q+S v4.4.5 (Proteome
Software, Inc., Portland, OR, USA). The peptide false discovery rate was
calculated with Scaffold Local FDR algorithm, and protein probabilities were
calculated using the Protein Prophet algorithm. Results were annotated with
human gene ontology information from the Gene Ontology Annotations Database
(ftp.ebi.ac.uk).
L.

Electron Microscopy—Early endosomes were precipitated on Protein G

Dynabeads as described above. Endosome-Dynabead complexes were pelleted
and fixed in 2% paraformaldehyde/2% glutaraldehyde in 0.1M phosphate buffer
(PB) overnight at 4°C. Pellets were subsequently washed in PB and fixed in 1%
osmium tetroxide (OsO4) in PB for 90 minutes at RT. Pellets were washed in PB
and dehydrated in an ethanol and propylene oxide series and embedded in
Durcupan epoxy resin. Ultrathin sections (80nm) were cut using a diamond knife

28

and collected on nickel mesh grids. The grids were stained with uranyl acetate
and lead citrate. Images were collected using a Hitachi HT7700 transmission
electron microscope. Individual vesicles were measured and quantified using
ImageJ (National Institutes of Health). The diameters of 651 endosomes were
measured, and the corrected mean diameter (D) of all endosomes was
calculated using the Fullman equation [D=(/2)*N/(1/d1+1/d2...1/dN)], where N
represents the total number of compartments, and d represents the diameter of
each individual compartment. This equation corrects for the differences in the
positioning of the vesicles within the ultrathin sections that were cut.
M.

siRNA Knock Down of RUFY1 and PTPN23—RUFY1 siRNA (siGENOME

SMARTpool Human RUFY1 Cat #M-016355-01, Lot #170711) and PTPN23
siRNA (siGENOME SMARTpool Human PTPN23 Cat #M-009417-01, Lot #
170711) were obtained from Dharmacon (Lafayette, CO). Each 5nmol stock
siRNA was reconstituted into 20μM aliquots. Scramble control siRNA (siCON)
was acquired from Integrated DNA Technologies (Coralville, IA). HeLa cells were
seeded at 500,000 cells/60mm dish and transfected with final concentrations of
50nM siRNA (or 50nM siCON) with INTERFERin (Polyplus Transfection,
Strasbourg, France) according to manufacturer’s instructions. The following day
(24 h post-transfection) cells were split and plated into 24-well dishes with NaOH
washed coverslips. Seventy-two hours post-transfection, cells were serum
starved for 2 h and then stimulated for the indicated time-points with fluorescent
10ng/mL Alexa-647-EGF (Invitrogen) ligand, followed by indirect
immunofluorescence.
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A 6-well dish was plated for each siRNA knock-down experiment. These
cells were harvested in RIPA buffer as previously described [63] 72-hours posttransfection and immunoblotted for RUFY1 and PTPN23 to ensure at least 90%
knock-down efficiency.
N.

Cell Counting—Twenty-four hours after siRNA knockdown, cells were

plated in 35mm dishes at a density of 100,000 cells/dish. Cells were incubated
for the indicated periods of time, and harvested using two distinct procedures.
Immediately prior to harvest, cells were imaged at 100x magnification on a Nikon
Eclipse Ti widefield epifluorescence microscope. To collect only viable cells,
dishes were first washed in RT PBS. The dishes were then incubated in 250uL
trypsin for 5 min until adherent cells were displaced. The cells were then
collected in a final volume of 1mL in DMEM and counted using a hemocytometer
[64]. The cells were then pelleted and harvested in RIPA buffer. To collect both
viable and inviable cells, cells were scraped and counted using a
hemocytometer, followed by pelleting and harvesting in RIPA buffer. Harvested
cells were then prepared for immunoblotting.
O.

125I-EGF

Radioligand Degradation—HeLa cells transfected with the

indicated siRNA were replated at a density of 200,000 cells/35mm dish. Seventytwo hours after transfection, cells were incubated for 7.5 minutes in ~0.05μg/mL
125I-EGF

(0.5mL per dish, ~5000 cpm/10μL) (catalog number NEX160,

PerkinElmer Life Sciences) at 37°C in binding buffer (DMEM, 10mM HEPES,
0.1% bovine serum albumin, pH 7.3). Cells were washed four times in binding
buffer to remove unbound 125I-EGF. Prewarmed medium was added to the cells,
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and they were returned to 37°C for the indicated periods of time. At each time
point, the medium was collected (secreted 125I-EGF). Remaining cells were then
solubilized in 1% NP-40, 20mM Tris, pH 7.4. Intact 125I-EGF was precipitated in
10% trichloroacetic acid and 1% bovine serum albumin for at least 60 minutes at
4°C. Intact 125I-EGF was separated from degraded 125I-EGF by centrifugation for
15 min at 14,000 rpm at 4°C. Radioactivity for each fraction was counted using a
PerkinElmer Wizard2 Gamma Counter [59].
P.

alamarBlue Viability Assay—HeLa cells were transfected with the

indicated siRNA and were replated 24 hours after transfection into 96-well dishes
at a density of either 5,000 or 10,000 cells/well. When the cells reached ~50%
confluency, they were serum starved for two hours, followed by 24-hour
incubation with either 0, 10, or 100ng/mL EGF to induce cell growth, or with
either 1μM AG1478 to inhibit EGFR activity or 1mM AG1478 to induce cell death.
After incubation, alamarBlue reagent (ThermoScientific, Waltham, MA) was
added at 10% of the total volume of media (i.e. 10μL) and incubated at 37°C and
5% CO2 for 2 hours. Fluorescence was then measured in an HT plate reader
using Gen5 BioTek software at 530nm excitation and 590nm emission [63].
Q.

Inhibition of EGFR Phosphorylation via AG1478—HeLa cells transfected

with the indicated siRNA were replated into either 96-well dishes or 35mm dishes
24 hours after transfection. Cells were treated with the indicated concentration
(either 1μM or 1mM) of AG1478 inhibitor (Cayman) for 24 hours prior to the
indicated time point [65]. Cells plated in 96-well dishes were serum starved for
two hours prior to treatment. Viability of cells in 96-well dishes was assessed
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using the alamarBlue assay. Cells in 35mm dishes were harvested to collect both
viable and inviable cells. Cells were scraped and counted using a
hemocytometer.
R.

Statistical Analyses—Unpaired student’s t-tests were used to determine

significance. A p value of less than 0.05 is considered significant, and is denoted
with a single asterisk (*). A p value of less than 0.001 is denoted with two
asterisks (**). A p value of less than 0.0005 is denoted with three asterisks (***).
A p value of less than 0.0001 is denoted with four asterisks (****).
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CHAPTER III
ISOLATION OF EGFR-CONTAINING EARLY ENDOSOMES
A. Introduction
A multitude of labs have studied the biochemical properties of various
endosomes, and have done so by isolating and separating endosomes from
cells. The process of breaking open cells to separate out and study specific
intracellular compartments is termed subcellular fractionation. Subcellular
fractionation can be applied and modified in many ways to study the contents
and functions of the various endocytic organelles. In this chapter, these methods
will be outlined to determine the strengths and weaknesses of each method.
The process of subcellular fractionation is generally made up of three
parts: lysing cells, separating cytosolic organelles, and isolating the target
organelle [66]. There are several ways to perform these steps, each of which
must also be optimized for the type of cells being used. Subcellular fractionation
can be utilized to study virtually any organelle or compartment inside cells.
However, the focus of this review will be on the application of these methods for
isolating endocytic organelles.
The first step of subcellular fractionation involves breaking open cells to
access internal compartments. The two major methods used to achieve this are
hypotonic and mechanical lysis. Hypotonic lysis of cells involves incubating cells
with a buffer containing lower than physiologic concentrations of either salt or
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sucrose until enough water moves into the cells via osmosis that the cells swell
and eventually burst. This is a very effective method for lysing cells, however, if
the organelles are continuously exposed to a hypotonic buffer, it is possible that
the organelles themselves risk being lysed as well. Some organelles, like
lysosomes, are sensitive to hypotonic lysis, while others like early endosomes
are not [67].
The second option for lysing cells is to use mechanical disruption. This
can be achieved by passaging cells through a syringe and a small needle
(typically 20-25 gauge), a ball-bearing homogenizer, or exposing cells to
sonication. All of these methods work to lyse cells by applying physical force to
the membrane of the cell. This method is less invasive than a hypotonic buffer
and is generally considered to have little effect on the integrity of the intracellular
compartments. However, it has been documented that these mechanical
techniques can cause the formation of new, non-physiologically relevant vesicles
as a result of hybrid fusion of distinct organelles [68]. The pros and cons of both
of these lysis methods should be considered when selecting a lysis method for
subcellular fractionation.
The second step of subcellular fractionation is separating intracellular
components. Typically after lysis, the cell lysates will be gently centrifuged to
pellet and remove large debris and nuclei. The nuclei can be discarded or used
for further analysis of nuclear proteins or DNA. The resulting supernatant
contains all cytosolic organelles, proteins, cytoskeleton, and the broken plasma
membrane. This is referred to as the post-nuclear supernatant (PNS). The
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contents of the PNS must then be separated out to make the target organelle
more accessible for the final isolation step of subcellular fractionation. The most
common methods of organelle separation utilize centrifugation. There are two
widely used types of centrifugation—rate zonal or differential, and isopycnic.
Rate zonal/differential centrifugation separates samples by size, and
isopycnic/density centrifugation separates samples by density. Creating a PNS
from cell lysates utilizes differential centrifugation. This type of separation can
also be used to separate any other subcellular compartments based on size.
Generally, increasingly higher speeds are required to pellet increasingly smaller
organelles. Large nuclei require low speeds to pellet (~600 x g), while much
smaller mitochondria and endosomes require much higher speeds to pellet
(~10,000-20,000 x g), and still smaller ribosomes and endoplasmic reticulum
fragments require extremely high speeds to pellet (~100,000 x g) [66].
Differential centrifugation is typically applied in sequence, beginning with
low speeds to pellet large organelles and collecting the supernatant to spin at
higher speeds to pellet smaller organelles. This process allows rapid and distinct
separation of target compartments. However, because several organelles can
sediment together due to size similarities, further separation methods may be
necessary for isolation of a pure population of the target organelle. Differential
centrifugation has been used for early/late endosome isolation [67, 69], but
recently isopycnic centrifugation has been more commonly used.
Isopycnic centrifugation requires the use of media to create a density
gradient. One type of density gradient is a continuous gradient. A continuous
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gradient is typically created with the use of a commercially available
heterogeneous media. During centrifugation, the media creates a spontaneous,
self-forming gradient throughout the sample tube—the least dense materials will
migrate to the top of the tube, and the densest materials will migrate to the
bottom. Percoll is an example of a commonly used density gradient media for
isopycnic centrifugation. Percoll is a mixture of colloidal silica coated with
polyvinylpyrrolidone. When cell lysates are mixed with and centrifuged in a
continuous gradient, organelles migrate to their isopycnic point within the
gradient. The gradients can then be collected in multiple “fractions” to separate
the contents with varying densities. An advantage of using a continuous gradient
is the ability to resolve compartments with minute differences in density.
However, a distinct disadvantage is that samples are diluted within the media,
decreasing their concentration. This becomes more of an issue when the target
organelle exhibits a range of densities and migrates within several fractions of
the gradient, further decreasing their concentration. For example, early and late
endosomes exhibit two separate ranges of densities (i.e. 1.035-1.042g/mL and
1.048-1.070g/mL, respectively) [50]. Although this increases the range of
fractions within the gradient that will contain these vesicles, their densities are
distinct enough to still separate both, with minimal overlap. Percoll gradients
have been utilized for decades to separate and isolate endosomes [70-72].
The second type of density gradient is a discontinuous gradient.
Discontinuous gradients are pre-formed and made of layers of media with
increasing densities. Sucrose is the most common media used to create a
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discontinuous gradient—also referred to as a “step” gradient. The final products
of a discontinuous gradient are distinct “fractions” that can be collected from the
“interface” between each layer of media. The number of interfaces/fractions in
the gradient is dependent upon the number of layers in the gradient, and the
quantity and density of the layers can be optimized based on the target
subcellular compartment being collected. This is a distinct advantage of using a
step gradient over a continuous gradient. The fractions from a discontinuous
gradient can also be collected in much smaller volumes, providing more
concentrated samples. While samples still migrate to their isopycnic point in a
step gradient, there are a finite number of isopycnic points as they correlate to
each distinct interface. As such, compartments collected at each fraction can
exhibit a wide range of densities. This feature can serve as either an advantage
or a disadvantage to this technique, depending on the target compartment. A
disadvantage is the increased potential for samples to be contaminated with
other subcellular organelles. Sucrose step gradients are also commonly used to
isolate endosomes [72, 73].
The third and final step of subcellular fractionation is purification of the
target organelle. Technically, this step is not a requirement for subcellular
fractionation. In fact, depending on the scientific question being asked, this step
is frequently omitted altogether. In many cases, the separation and enrichment of
target organelles with density gradients is sufficient for further study with
biochemical techniques [59, 65]. However, obtaining a pure organelle sample is
essential for analyzing the proteome of a compartment. Multiple platforms can be
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used for this step, and it is arguably the most important component of organelle
isolation. Typically, in order to isolate a particular cellular compartment, a protein
specific to the compartment of interest will be targeted. For example, antibodies
against RAB11a, a protein specifically associated with recycling endosomes,
were conjugated to magnetic beads, incubated with subcellular fractions, and
placed on a magnet to purify recycling endosomes in the work of Silvis et al. [73].
The affinity of the antibody for its antigen, as well as the substrate to which the
antibody is conjugated, are two critical components of this method [66]. Magnetic
(Dynabeads), sepharose, and agarose beads are commercially available binding
substrates with either Protein A or Protein G (or a mixture of both) coupled to the
beads. Protein A & G are immunoglobulin-binding proteins that should be
selected based on the source of the monoclonal antibody they will bind. The
material make-up of the beads (Dynabeads, agarose, or sepharose) can also be
selected based on their properties. Agarose and sepharose beads must be
centrifuged or loaded on a column to isolate the beads and their bound
organelles. Dynabeads, however, can be placed on a magnet and the
supernatant removed with a pipette. Magnetic beads generally provide a gentler
platform for isolating the target organelle, however they tend to be more
expensive. The target organelles can be eluted off of the beads using either pH
washes or a protein solubilizing buffer.
Various modifications of these methods of subcellular fractionation
detailed in this chapter were tested in order to develop a protocol optimized for
the isolation of early endosomes from HeLa cells to study EGFR signaling from
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these compartments.

B. Results1
EGF colocalizes with EEA1-positive vesicles
To determine the time-point at which the EGFR was maximally localized to
the early endosome, we used indirect immunofluorescence probing for the early
endosome marker, Early Endosome Autoantigen 1 (EEA1) [74] following
Alexa647-EGF treatment (Figure 3.1). The addition of EGF induces a timedependent redistribution of EGFR into the cytosol and colocalization with EEA1.
Fifteen minutes after the addition of EGF, there is a peak accumulation of EGF
co-staining with EEA1. These kinetics of endocytic trafficking are consistent with
previous reports [59, 75]. After 30 minutes of EGF treatment, there is a decrease
in EGF and EEA1 co-staining, which is consistent with reports that the
EGF:EGFR complex is trafficked out of the early endosome 30-60 minutes after
EGF stimulation [76, 77]. Subsequent experiments use 15 minutes of EGF
treatment to maximize the receptor association with the early endosome.

EGFR colocalizes with early endosomal proteins in isotonic Percoll gradient
fractions
To biochemically enrich the early endosome population, PNS was
prepared from HeLa cells treated without and with EGF, and separated on a 17%
isotonic Percoll gradient [78]. Fractions of Percoll gradients were subjected to
immunoblot for EEA1, EGFR, phosphorylated EGFR (pY1068), transferrin

1This

research was originally published in the Journal of Biological Chemistry. Gosney JA et al. J
Cell Bio. 2018 Mar 9. Reprint with permission. © the Authors.

39

Figure 3.1 EGF colocalization with EEA1-positive vesicles. Serum-starved
HeLa cells were pulse-chased with Alexa-647-EGF (10ng/mL) for 0, 5, 15, and
30 min. Cells were fixed and processed for indirect immunofluorescence using an
EEA1 antibody and fluorescently-labeled secondary antibody (goat anti-rabbit
Alexa488). Scale bar=20μm. A. Images are representative of three independent
experiments. B. The extent of colocalization between EGF or EGFR and EEA1
was measured as described in Chapter II. Data are plotted as the percent
colocalization for each time point (four images were taken per time point, i.e.
each data point measured one image). Three independent experiments are
represented with three distinct bars. Approximately 300 cells total were analyzed
per time point per condition, per experiment. Scale bars=20μm. Images were
quantified using ImageJ software. A Pearson’s correlation was calculated for
each of the three experiments comparing EGF fluorescence to total EEA1
fluorescence: r=0.8790, r=0.9608, and r=0.9659.
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receptor (TfnR) (early/recycling endosome marker), and late endosome/
lysosome associated membrane protein-2 (LAMP2) (late endosome/lysosome
marker) (Figure 3.2A). EGFR peaked in the same fractions as EEA1 and TfnR
(Rf ~0.25-0.10) independent of EGF treatment. The gradient distribution of
LAMP2 indicated that there is a distinct, but not complete separation of early and
late endosomes/lysosomes within the Percoll gradient, although a lesser amount
of LAMP2 is present in the early endosome peak fractions. This less intense
peak of LAMP2 increases upon EGF ligand stimulation. Phosphorylated EGFR
(at tyrosine residue 1068, i.e. pY1068) was detected to differentiate between
active and inactive receptors. There was a low basal level of phosphorylation in
the unstimulated fractions, likely reflecting the population of constitutively
recycling EGFR. These levels increased upon EGF stimulation and
corresponded with EEA1 peak fractions.
We also monitored the distribution of Na/K-ATPase (plasma membrane
marker) and Calnexin (endoplasmic reticulum marker) in Percoll gradient
fractions and found that both markers peaked in the same fractions as EEA1 and
EGFR. These immunoblots were quantified and the relative distribution of each
protein in the Percoll gradient was plotted (Figure 3.2B). We noticed that Na/KATPase has peak concentrations in the same fractions as EEA1. This is because
the density of plasma membrane is very close to the density of early endosomes
(i.e. 1.045g/mL) [79]. Na/K-ATPase has also been shown to undergo endocytosis
under certain conditions, and its presence in these fractions may also indicate
and early endosomal localization [80-82]. These data highlighted that despite
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Figure 3.2 Total and phosphorylated EGFR colocalize with early endosomal
markers following isotonic Percoll gradient fractionation. A. PNS was
prepared from HeLa cells treated with and without EGF (10ng/mL) for 15 min.
PNS was resolved on a 17% isotonic Percoll gradient, fractionated, and resolved
by 7.5% SDS-PAGE. Proteins were transferred to a nitrocellulose membrane and
immunoblotted for phosphorylated (pY1068) and total EGFR as well as the
following marker proteins: EEA1 (early endosomes), TfnR (early and recycling
endosomes), LAMP2 (late endosomes and lysosomes), Na/K-ATPase (plasma
membrane), and Calnexin (endoplasmic reticulum). Immunoblots are
representative of three independent experiments. B. Relative intensity of the
immunoblots in A. Circles on the x-axis represent density bead migration (Rf
~0.93=1.109g/mL, ~0.91=1.070g/mL, ~0.89=1.057g/mL, ~0.59=1.049g/mL,
~0.20=1.042g/mL).
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significant enrichment of the early endosome, there is a need for additional
endosome purification.

EEA1 targeting antibodies purify early endosomes
Due to the presence of other contaminating organelles in the EEA1
fractions, an affinity purification strategy was used to further isolate the enriched
early endosomes. Percoll gradient fractions with an Rf of ~0.25-0.10 (~1.04g/mL1.03g/mL density) were immunoisolated using an EEA1 monoclonal antibody
(Cell Signaling) and Protein G conjugated to magnetic Dynabeads (Invitrogen).
Magnetic beads were selected for the purification strategy to provide a rapid and
gentle platform, as the substrate can be quickly and easily precipitated on a
magnet. The steps of this newly developed purification strategy are outlined in
Figure 3.3. Samples from each step of the process were collected and
immunoblotted for multiple organelle marker proteins (Figure 3.4A). This
strategy yielded 100% pull-down of EEA1, and approximately 7% pull-down of
the constitutively recycled TfnR in both EGF stimulated and unstimulated
samples. Although we expected greater pull-down of TfnR, it is not surprising as
the constitutively recycled receptor is also localized to the plasma membrane and
recycling endosomes. Alternatively, this low yield of TfnR could indicate that the
early endosomes are not remaining intact throughout the isolation procedure.
Immunoisolated fractions contained early endosome markers (e.g. EEA1 and
TfnR) and were largely devoid of markers of other organelles (LAMP2, Na/KATPase, and Calnexin) (Figure 3.4B). EGF treatment increased total and
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Figure 3.3 Schematic of the Percoll Gradient purification protocol.
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phosphorylated EGFR. Together, these data indicate we are successfully
enriching EGFR-containing early endosomes. In both samples, the majority of
phosphorylated EGFR was detected in the pass-through and not in the elution.
This result, along with the low levels of TfnR in the elution, could also suggest
that the early endosomes do not remain intact during isolation. However, EGF
stimulation increases the amount of total EGFR precipitated with EEA1 more
than 3-fold. Further, the consistent precipitation of virtually 100% of EEA1 from
enriched gradient fractions indicates that these membrane preparations are
highly specific for early endosomes.
The absence of other organelle marker proteins was used as a negative
control for early endosome precipitation. The vast majority of LAMP2, Na/KATPase, and Calnexin were present in the pass-through of both samples.
However, low but detectable amounts were present in the elutions. It is possible
that their presence indicates contamination in the preparations. It is not likely that
Calnexin would be found in early endosomes under normal conditions, however
we cannot completely rule out this possibility. LAMP2 on the other hand was
detected in the Percoll gradient early endosome fractions at low levels (see
Figure 3.2), and because it is involved in trafficking, it is likely that its presence in
the sample is representative of hybrid endosomes that are undergoing
maturation [83]. Very low levels of Na/K-ATPase in the elutions indicates that
there is minimal but detectable plasma membrane contamination.

EEA1-purified compartments exhibit early endosome morphology
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Figure 3.4 Affinity purification of early endosomes from Percoll gradient
fractions. A. PNS from HeLa cells treated with or without EGF (10ng/mL) were
separated on a 17% isotonic Percoll gradient. Fractions containing early
endosome markers were immunoisolated using an EEA1 antibody as outlined in
Chapter II. Samples were loaded by percent of total sample volume and proteins
were resolved on a 7.5% SDS-PAGE. E=elution, PT=pass through, PF=pooled
fractions (Percoll gradient fractions with Rf values of ~0.25-0.10), PNS=postnuclear supernatant. Percent of sample total is noted above each lane.
Membranes were immunoblotted for EEA1, total EGFR, phosphoEGFR
(pY1068), TfnR, LAMP2, Na/K-ATPase, and Calnexin. Data are representative of
three independent experiments. B. Quantifications are shown as percentages of
the total IP sample (i.e., elution + pass-through=100%). Data are plotted ± S.D.
C. Electron micrograph of immunoisolated early endosomes. A representative
micrograph of Dynabeads and early endosomes (30,000x). Scale bar=200nm.
The diameters of 651 individual endosomes were measured using ImageJ
software. Correcting with the Fullman equation, the mean diameter of the
endosomes was calculated to be 68.63nm. A histogram of endosome size is
inset in panel C. Arrows indicate endosomes.
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While the biochemical data confirmed that early endosome proteins were
being purified and other organelles excluded, we wanted to determine whether
intact vesicles or membrane fragments were being pulled down. Early
endosomes were enriched in Percoll gradients and affinity purified using an
EEA1 antibody and magnetic beads. The magnetic beads-endosome complexes
were fixed and stained for transmission electron microscopy (TEM) as outlined in
Chapter II. The mean (± standard deviation) diameter (corrected using the
Fullman equation) of the vesicles was 68.63 ±26.74nm (Figure 3.4C).
TEM has been used by many investigators to visualize endosomes. Early
endosomes appear as round structures with low density staining, while late
endosomes stain darker and contain intraluminal vesicles. This makes the two
endosome types easy to distinguish using TEM. The endosomes we isolated
exhibit staining, morphology and size distribution that is indistinguishable from
reports of early endosomes in the literature [84].
Mass spectrometry reveals early endosome proteins and novel EGF-dependent
associations
Affinity purified endosomes were collected and subjected to liquid
chromatography/tandem mass spectrometry as outlined in Chapter II. The
resulting data were uploaded into a repository
(ftp://massive.ucsd.edu/MSV000081692). Amongst all three replicates, a total of
more than 900 distinct proteins were detected. Here, we report an abridged list of
proteins in Figure 3.5. Multiple proteins with known associations and functions
with early endosomes and endocytosis were present with and without EGF
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Figure 3.5 Early endosome and membrane trafficking proteins. Proteins
were detected in all EGF-treated and untreated samples from three independent
LC-MS/MS analyses of EEA1-affinity purified early endosomes. Early
endosomes from HeLa cells treated with ±10ng/mL EGF for 15 min were
enriched in a Percoll gradient and affinity purified using an EEA1 monoclonal
antibody. Purified endosomes were eluted in sample buffer, resolved on a 12%
SDS-PAGE, stained with Coomassie and subjected to LC-MS/MS as outlined in
Chapter II. Data are compiled from 3 independent experiments and quantified
using intensity based absolute quantification (iBAQ). A complete list of proteins
can be found at ftp://massive.ucsd.edu/MSV000081692.
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treatment, including sorting nexins, secretory carrier-associated membrane
proteins, EEA1, and TfnR. These data, along with the TEM images, validate the
early endosome purification technique.
We also compared the protein composition of the endosomes collected
from cells treated with and without EGF ligand. As expected, both EGF treated
and untreated samples contain EEA1, as well as transport receptors localized to
the early endosome (e.g. TfnR, LDLR, and IGF2R) (Figure 3.6). This
methodology was indirectly validated by the presence of proteins involved in
endocytosis, intracellular trafficking, membrane recycling, etc. Among the
proteins identified, there were five that were specifically present in EGF-treated
samples: EGFR, CCDC51, PTPN23, RUFY1, and STOML2 (Figure 3.6). Of
these proteins, PTPN23 and RUFY1 play known roles in early endosome
trafficking and cargo sorting [85, 86]. STOML2 is a mitochondrial protein with well
documented roles in mitochondrial and cardiolipin biogenesis [87, 88]. CCDC51
is a recently discovered coiled coil domain containing protein that has only been
described based on its structure. We have used PTPN23, RUFY1, and STOML2
to validate EGF-dependent protein associations with the early endosome.

C. Discussion
In this study, we developed a novel method for enriching early
endosomes. Immunoblotting of Percoll gradient fractions validated the separation
of early and late endosomes using EEA1 and LAMP2 as respective marker
proteins. In Figure 3.2, there is a discreet amount of LAMP2 staining in the EEA1
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Figure 3.6 Receptors detected in early endosomes and proteins that
associate with the early endosome in an EGF-dependent manner. Early
endosomes from HeLa cells treated with ±10ng/mL EGF for 15 min were
enriched in a Percoll gradient and affinity purified using an EEA1 monoclonal
antibody. Purified endosomes were eluted in sample buffer, resolved on a 12%
SDS-PAGE, stained with Coomassie and subjected to LC-MS/MS as outlined in
Chapter II. Data are compiled from 3 independent experiments and quantified
using intensity based absolute quantification (iBAQ). Receptors listed (i.e. TFRC,
IGF2R, LDLR) and EEA1 were detected in EGF treated and untreated samples
in all three replicates. EGFR & the four novel proteins were detected in only the
EGF treated samples, and in at least two of the three replicates.
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peak fractions. While these results could be interpreted as incomplete separation
of early and late endosomes, we propose that this lower density peak of LAMP2
represents a population of early endosomes that are maturing into late
endosomes. The literature supports this notion, particularly regarding EGFR
internalization driving endosomal maturation [51]. This is supported by the
increased intensity of the lower density LAMP2 peak after EGF stimulation.
Further, the peak of EGFR aligns with the EEA1 peak, independent of EGF
treatment. The presence of EGFR in these fractions without ligand stimulation
suggests that these receptors could be present in early endosomes, plasma
membrane, or endoplasmic reticulum membranes. For this reason, the affinity
purification strategy was applied to the gradient enriched early endosomes.
Biochemical and cell biological assays (TEM, immunoblotting, and mass
spectrometry) validated the purification strategy developed in this study. These
assays confirmed that the isolated endosomes were of the proper size and
morphology, contained many expected resident proteins, and excluded markers
of other organelles. TEM images also confirmed that the isolated compartments
exhibit morphology characteristic of early endosomes.
Despite the isolation protocol being designed to be rapid and gentle, there
is always the possibility that the endosomes did not remain intact during isolation,
and some associated proteins were lost. TEM was employed to test for this
possibility (Figure 3.4C), and the data from those images suggest that the
compartments collected were mostly intact.
This method for endosome isolation can be adapted to isolate many other
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organelles, by selecting an antibody that targets an antigen with high specificity
for the organelle of interest. LC-MS/MS provides the sensitivity and unbiased
detection in this screen. While other labs have monitored the subcellular location
of other trafficking and signaling proteins, they have relied primarily upon
biochemical techniques that require a previous knowledge or predication as to
what proteins to monitor. The process developed in this study supersedes this
prerequisite. Using this technique, we report an EGF-dependent association of
novel proteins with the early endosome. This protocol can be extrapolated to
study the spatial regulation of other endocytosed receptors, including the other
ErbB family members (i.e. Her2, ErbB3, and ErbB4), and other RTKs such as
PDGFR, IGF1-R, and VEGFR.
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CHAPTER IV
THE RELATIONSHIP OF RUFY1 AND PTPN23 WITH EARLY ENDOSOMES
A. Introduction
Thus far, the scope of this study has taken a very focused viewpoint on
the protein composition of early endosomes. For the sake of simplicity and
relevance, we have stayed within the realm of proteins that have been reported
in the literature to play a role in EGFR trafficking and signaling. In this chapter,
we will expand that focus to include the novel and not-so-novel proteins that we
found to associate with EGFR in endosomes. We detected four proteins that
associated with isolated early endosomes in an EGF-dependent manner:
RUFY1, PTPN23, STOML2, and CCDC51. Both RUFY1 and PTPN23 have been
previously reported to be involved in endosomal trafficking, while STOML2 and
CCDC51 have not. This introduction will focus on what is currently known in the
literature about the roles of these proteins in endosomal trafficking and signaling.
Due to the lack of information on STOML2 and CCDC51 in these roles, this
review focuses heavily on RUFY1 and PTPN23.

i. RUFY1
RUFY1 is a RAB4 effector protein and is commonly referred to by its
isoforms rapib4 and rabip4’. The name RUFY1 derives from its structure, as the
protein contains both a RUN domain and a FYVE domain. The RUFY1 family of
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proteins contain an N-terminal RUN domain that binds proteins, followed by two
coiled-coil domains, and a C-terminal FYVE finger which binds phosphatidylinositol 3-phosphate (Figure 4.1A) [89].
The first work and initial discovery of the RUFY1 protein was published in
2001 [86]. Cormont and colleagues were searching for a protein that specifically
binds to active, GTP-bound RAB4, and thus cloned and first identified RUFY1,
initially named rabip4 (RAB4-interacting protein) [86]. Using confocal and
electron microscopy, they characterized rabip4 as associating with EEA1containing early endosomes, but not with RAB11-containing recycling
endosomes. Their initial cloning techniques uncovered the coiled-coil domains
and the FYVE domain of the protein, but not the RUN domain. The RUN domain
of rabip4 was discovered and published later that same year by the same group
[89]. They characterized the RUN domain as being responsible for tethering the
protein to endosomal microdomains. This work also proposed that rabip4 may
lead to sorting and recycling endosome fusion.
In 2002, Yang and colleagues discovered what they believed to be a
“novel” protein identical to rabip4, and coined the name RUFY1 [90]. This protein
was discovered by screening for new effectors of the protein Etk, a tyrosine
kinase (commonly referred to as BMX). They discovered that phosphorylation of
RUFY1 by Etk was necessary for RUFY1 to localize to endosome membranes. In
this study, they co-transfected B82L cells with EGFR, Etk, and various mutations
of the FYVE domain of RUFY1 and monitored their subcellular localization via
immunofluorescence. These researchers discovered that Etk plays an important
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Figure 4.1 Secondary protein structure of RUFY1 and PTPN23. A. A
schematic of the secondary protein structure of RUFY1. The protein consists of
an N-terminal RUN domain, two coiled-coil domains, and a C-terminal FYVE
domain. B. A schematic of the secondary structure of PTPN23. The protein
consists of an N-terminal BRO-homology domain, a V-shaped homology domain,
a histidine-rich domain, a PTP-like domain, and a proteolytic degradation
targeting motif. Regions where STAM, K63 ubiquitin, and UBAP1 binding occur
are also labeled. Structures were modeled after work done by Mari et al. and
Gingras et al. [89, 91]
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role in EGFR localization. When Etk was co-transfected with EGFR, there was a
significant increase in the localization of EGFR to the plasma membrane of cells.
Conversely, co-transfecting the FYVE domain of RUFY1 into these cells caused
a reversal of the Etk-induced localization of EGFR to the cell periphery. To
support this claim even further, they found that a mutant RUFY1 FYVE domain
that lacked the Etk-binding site did not induce this effect. These interactions
between RUFY1 and Etk, and between Etk and EGFR, are likely key factors that
influence this work’s findings in RUFY1 KD cells.
More recent studies have further elucidated the role of RUFY1 in
endocytic trafficking. It was initially accepted that the activity of RUFY1 in
endosomes was restricted to early and recycling endosomes. Several studies
have shown that RUFY1 activity in the early phases of endocytic trafficking plays
a role in periodontal disease, early onset Alzheimer’s disease, and type 2
diabetes mellitus [92-94]. While the role of RUFY1 and its interactions with early
endocytic RAB proteins (including RAB4, RAB5, and RAB14) have been well
studied, it has also been shown to mediate lysosome distribution in conjunction
with the protein AP-3 [95-97]. It is clear that all of the functions and interactions
between RUFY1 and other proteins have not yet been uncovered, and the field of
RUFY1 research is still in its youth.

ii. PTPN23
In 1998, a novel protein was discovered in rat cardiomyocytes called PTPTD14 [98]. The abbreviation PTP stands for protein tyrosine phosphatase. Soon
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after, the human homolog was discovered, and was coined histidine domain
phosphotyrosine phosphatase (HD-PTP) [99]. The protein was referred to as HDPTP in the literature until 2009, when Gingras and colleagues discovered that the
protein was distinct from other PTP proteins, and coined the name tyrosineprotein phosphatase non-receptor type 23 (PTPN23) [100]. Currently, there is not
a consensus on the name of this protein, and it is frequently referred to as both
HD-PTP and PTPN23. For the sake of simplicity, we refer to the protein as
PTPN23 from this point forward.
PTPN23 has been well studied and characterized in its role as an
endosomal protein. The major function of this protein is to sort ubiquitinated
endocytic cargo into multivesicular bodies (MVBs) via ubiquitin binding and the
ESCRT-I complex (Figure 4.1B). PTPN23 was first discovered about 20 years
ago, by Cao and Zhou in 1998 [98]. They sought to discover new protein tyrosine
phosphatases in their search to understand their role in myocardial signaling in
rat neonatal cardiomyocytes. Cloning and expressing this protein into NIH-3T3
cells revealed that the protein localized to “vesicle-like structures,” and inhibited
Ha-ras-mediated transformation of these cells [98]. Two years later, researchers
discovered that the gene for this protein was located at a specific loci on
chromosome 3 that was frequently deleted in cancer [99]. These studies showed
that this novel protein seems to play some sort of tumor suppressor role.
Multiple studies in the early 2000s would corroborate the role of PTPN23
as a tumor suppressor. It was implicated in angiogenesis and cell migration in
several studies by Mariotti and Maier [101-104]. It was hypothesized by this
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group and others that the mechanism of PTPN23 activity in these processes was
by its catalytic activity as a phosphatase. However, in 2009, Gingras and
colleagues performed an enzymatic analysis on the protein and discovered that
PTPN23 has neither tyrosine phosphatase nor lipid phosphatase activity [100],
changing the way the field approached the function of PTPN23.
The Woodman group began studying PTPN23 in relation to the protein
Alix. The Alix protein was known to be structurally similar to the yeast protein
Bro1p, but did exhibit the same MVB sorting activity as Bro1p [85]. In their search
for determining the role of Alix in MVB sorting, they found that PTPN23 is a Bro1
domain containing protein with critical implications in MVB sorting. Knocking
down PTPN23 resulted in a 94% reduction in MVB sorting of HRP-conjugated
EGF ligand [85]. Further studies confirmed this finding and extrapolated upon its
mechanism. PTPN23 plays a critical role in MVB cargo sorting via interactions
with UBPY, CHMP4B, UBAP1, SARA, and other ESCRT-0 complex proteins
[105-107]. The mechanisms of PTPN23 cargo sorting of EGFR and other
receptors has been and continues to be well understood.

iii. CCDC51
The protein CCDC51 was also found to associate with early endosomes in
an EGF-dependent manner. At the current time, there have been zero studies on
the function of CCDC51. The only known information about this protein is that it
was named for its structure (coiled-coil domain containing protein 51).
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iv. STOML2
STOML2 has been well characterized, however, the literature seems to
give no guidance as to the nature of the possible role of this protein in EGFR
signaling or trafficking. The function of STOML2 has only been studied in
mitochondria, and it is known to play important roles in mitochondrial regulation
and biogenesis. There also seems to be some confusion in the literature as to
the name for STOML2, as it is sometimes referred to as SLP-2. It is important to
note that SLP-2 is sometimes used to describe a separate protein,
synaptotagmin-like protein 2.
In light of the discovery of an association of STOML2 with early
endosomes, the author would like to point out that there are a few minor
indications in the literature that could be useful guides for future research into this
function of STOML2. First, it seems that a family member of STOML2, STOML1
(sometimes called SLP-1), has been shown to associate with late endosomes
[108]. Second, and even more intriguing is the well-documented but unknown
role of STOML2 in cancers. STOML2 has been found to be overexpressed in
multiple types of cancer, including esophageal squamous cell carcinoma
(ESCC), glioma, and breast cancer [109-111]. STOML2 overexpression has also
been linked to poor patient outcomes [111-113]. This presents a potential avenue
for future studies: if STOML2 associates with early endosomes in HeLa cells,
perhaps the mislocalization of STOML2 away from mitochondria and into
endosomes plays a role in driving cancer cell proliferation.
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B. Results1
Analysis of the candidate proteins and other downstream effectors in early
endosomes
To determine whether these proteins associate with the early endosome in
an EGF-dependent manner, HeLa cells were treated with and without EGF,
prepared as a PNS, and separated over an isotonic Percoll gradient. The
gradient fractions were immunoblotted for the candidate proteins PTPN23,
RUFY1, and STOML2. It was expected that, as primarily early endosomeassociated proteins, RUFY1 and PTPN23 would be found in the same fractions
in which EEA1 peaks, or those with an Rf value of ~0.25-0.10. There was a peak
concentration of both proteins in the EEA1 peak fractions (Figure 4.2). STOML2,
being a predominately mitochondria-associated protein, was expected to be
found in the densest fractions, as mitochondria have a density of ~1.1g/ml.
Interestingly, STOML2 staining was somewhat diffuse throughout the gradient
and decreased in the EEA1 peak fractions. This suggests the possibility that
STOML2 is not found strictly within mitochondria, and may be associated with
other organelles of various densities. The concentration of RUFY1 appeared to
increase in the EEA1 peak fractions upon EGF stimulation (Figure 4.2B).
Although RUFY1 (and STOML2) appear in these fractions without EGF
stimulation as well, this likely indicates the association of these proteins with
other organelles in these fractions, such as plasma membrane. RUFY1 is known
to associate with early endosomes regardless of EGFR activation, and it has also
been suggested that RUFY1 may shuttle between the plasma membrane and
1This

research was originally published in the Journal of Biological Chemistry. Gosney JA et al. J
Cell Bio. 2018 Mar 9. Reprint with permission. © the Authors.
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Figure 4.2 Immunoblot validation of candidate proteins from
immunoisolated early endosomes. HeLa cells treated with ±10ng/mL EGF
were subjected to Percoll gradient fractionation and EEA1-targeted
immunoisolation as described in Chapter II. A. Percoll gradient fractions were
resolved on a 10% SDS-PAGE and immunoblotted for EEA1, PTPN23, RUFY1,
or STOML2. B. Quantification of the immunoblots in A.

61

endosomes [90] and can likely be found localized to both membrane populations.

RUFY1, STOML2, and PTPN23 colocalize with EGF and EEA1
We used indirect immunofluorescence to monitor the kinetics of
association of the candidate proteins with the early endosome. HeLa cells were
pulse-labeled with fluorescently-labeled EGF (Alexa-647-EGF) for 0-30 minutes.
Cells were fixed and immunostained for EEA1 and each of the candidate
proteins. For all three proteins, there was a time-dependent association with the
labeled EGF. This is consistent with the model of the liganded receptor
internalizing and trafficking to the early endosome. RUFY1 and PTPN23
colocalized with EEA1 independent of EGF treatment (Figure 4.3A and 4.3C),
whereas STOML2 had low levels of colocalization with EEA1 that increased with
EGF treatment (Figure 4.3B).

Loss of PTPN23 or RUFY1 changes the kinetics of EGFR endocytic trafficking
We used RNA interference to knock down PTPN23 and RUFY1 in HeLa
cells to determine the functional relevance of these proteins in EGFR trafficking.
HeLa cells were transfected with 50nM siRNA or siCON (scramble control) for 72
hours, serum starved, and treated with 10ng/mL Alexa-647-EGF ligand for 0-120minutes as described in Chapter II. Each experiment was repeated in triplicate,
and a knockdown efficiency of more than 90% was achieved for each experiment
(Figure 4.4D).
Loss of RUFY1 resulted in sustained activation of EGFR, as evidenced by
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Figure 4.3 RUFY1, STOML2, and PTPN23 colocalize with early endosomes
and internalized EGF. A-C. HeLa cells were pulse-labeled with 10ng/mL
AlexaFluor-647-EGF ligand (Invitrogen) for 0, 5, 10, 15, 20 and 30 minutes,
followed by fixation in 4% paraformaldehyde. The cells were permeabilized and
immunostained for EEA1 and either RUFY1, STOML2, or PTPN23 and
visualized using either a goat anti-rabbit Alexa568 or goat anti-mouse Alexa-488,
respectively. Images are representative of 0, 5, 15, and 30-minute time-points
from three independent experiments. The extent of colocalization between EGF
and each candidate protein or EEA1 and each candidate protein was measured
as described in Chapter II. Data are plotted as the percent colocalization for each
time point. Approximately 300 cells were analyzed per time point per condition,
per experiment. Scale bar=20μm. Images were quantified using ImageJ
software.
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Figure 4.4 EGF and EGFR colocalization with EEA1 in siCON, RUFY1 KD,
and PTPN23 KD cells. A-C. HeLa cells were incubated with scramble control
(siCON), RUFY1, or PTPN23 siRNA for 72 hours prior to serum starving. The
serum starved cells were pulse-labeled with 10ng/mL AlexaFluor-647-EGF ligand
(Invitrogen) for 0, 15, 30, 60, and 120 minutes, followed by fixation in 4%
paraformaldehyde. The cells were permeabilized and immunostained for EEA1
and EGFR and visualized using either a goat anti-rabbit Alexa488 or goat antimouse Alexa-568, respectively. Images are representative of time-points from
three independent experiments. The extent of colocalization between EGF or
EGFR and EEA1 was measured as described in Chapter II. Data are plotted as
the percent colocalization for each time point. Approximately 300 cells were
analyzed per time point per condition, per experiment. Scale bars=20μm. Images
were quantified using ImageJ software. D. A representative immunoblot from
each knock-down experiment, probing for PTPN23, RUFY1, and α-tubulin. For
each knock-down experiment, samples were loaded in multiple protein
concentrations (20µg, 10µg, and 5µg) and the percent knockdown was
calculated. Only experiments with a knock-down efficiency of >90% were used.
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the prolonged colocalization of EGF ligand with EEA1 at 60- and 120- minutes
when compared to siCON (Figure 4.4A and 4.4B). A similar prolonged
association of EGF ligand with EEA1 is also seen in the PTPN23 KD samples
(Figure 4.4C). In addition, the loss of PTPN23 in HeLa cells also yields an
increase in the colocalization of total EGFR with EEA1. This suggests that EGFR
is sequestered in early endosomes after activation, and that PTPN23 plays a role
in the endocytic progression (e.g. MVB cargo sorting or endosomal maturation)
of the receptor. This is consistent with the results of PTPN23 KD in other labs
[85, 107, 114].

PTPN23 loss results in slowed degradation and secretion of 125I-EGF
In order to further understand the roles of PTPN23 and RUFY1 in EGFR
trafficking, we used a radiolabeled EGFR ligand (125I-EGF) and monitored its
degradation and secretion in knock-down cell lines. RNAi was used to knockdown PTPN23 and RUFY1 in HeLa cells, and these cells were then stimulated
with 125I-EGF for 7.5 minutes. Unbound radioligand was washed off of the cells,
and the dishes of cells were incubated for the various periods of time. At each
time-point, the media was collected from each dish, which contained any
radioligand that was secreted from the cells during the incubation process. The
cells were then solubilized, and intact proteins were precipitated out via
centrifugation. The supernatant contained degraded proteins that did not
precipitate. The radioactivity in the media (secreted), pellet (intact), and
supernatant (degraded) were counted on a gamma counter (Figure 4.5).
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Figure 4.5 125I-EGF radioligand trafficking in RUFY1 KD and PTPN23 KD
cells. HeLa cells were transfected with the indicated siRNA for 72 hours prior
to treatment. Cells were then treated with 0.05μg/mL 125I-EGF as described in
Chapter II and incubated at 37°C for the indicated period of time. At each timepoint, the media was collected and the cells were solubilized. A. Intracellular
degraded and B. extracellular (secreted) 125I-EGF radioactivity was counted in
a PerkinElmer Wizard2 Gamma Counter and divided by the total radioactivity
of each sample to calculate the percent degraded or secreted. C. Total
radioactivity (cpm) of the collected media measured in each sample. All data
are plotted as the mean ± standard deviation (n=3).
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There was a significant decrease in 125I-EGF ligand degradation in PTPN23 KD
cells (Figure 4.5A). This result was expected, and is consistent with other
PTPN23 KD studies in the literature. There was also a significant decrease in the
secretion of 125I-EGF in these cells (Figure 4.5B). This supports the notion that
there is less degradation of the ligand:receptor complex, and therefore less
degraded ligand secreted from the cells. These data support the claim that
PTPN23 is crucial for proper sorting of cargo into MVBs prior to lysosomal
degradation.
While reviewing the raw data, we noticed that there was an increase in
the total radioactivity in the media of the RUFY1 KD cells (Figure 4.5C). Even
though there was not an increase in the percent of ligand secretion in the
samples, there was still more radioactivity in all of the samples taken from
these cells. We hypothesized that the increase in total radioactivity may be an
artifact of an increase in total cell number of the RUFY1 KD cells. This was
another observation we made during the propagation and experimentation
using these cells. The RUFY1 KD cells seemed to grow more rapidly in
comparison to siCON control HeLa cells. Next, we decided to quantify this
change, and determine if it was EGFR-mediated.

RUFY1 loss leads to a significant increase in cell number
In order to quantify differences in cell number due to RUFY1 and
PTPN23 loss, HeLa cells were transfected with 50nM siRNA for 24-hours prior
to replating at 100,000 cells in 35mm dishes. The dishes were then incubated
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Figure 4.6 Cell number of siCON, RUFY1 KD, and PTPN23 KD HeLa cells
under various conditions. A-C. HeLa cells were transfected with the
indicated siRNA for the indicated time-points. Twenty-four hours after
transfection, cells were split and plated at 100,000 cells in 35mm dishes for
each time-point. They were then allowed to proliferate and dishes were
harvested every twenty-four hours. Cells were harvested as indicated and as
outlined in detail in Chapter II. Cells were counted using a hemocytometer
after harvest. Cells treated with AG1478 were incubated with 1μM AG1478 for
24-hours prior to harvest. All data are plotted as the mean ± the standard
deviation (n=3).
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under growth conditions and cells were harvested and counted every 24hours. To collect viable cells, dishes were washed in PBS, trypsinized, and
counted with a hemocytometer. There was a statistically significant increase in
the number of viable RUFY1 KD cells as compared to siCON (Figure 4.6A).
In addition to counting viable cells, we also counted viable and inviable
cells under the same experimental conditions. While monitoring the cells under a
microscope over time, there appeared to be more dead cells floating in the media
of dishes with PTPN23 KD and siCON cells compared to RUFY1 KD cells. For
this reason we repeated the cell counting experiments, but adjusted the protocol
to collect both viable and inviable cells from the dishes.
In order to harvest the entire population of cells on the dish, we used a cell
scraper to harvest all of the cells in the media. The cells were counted on a
hemocytometer, and then pelleted and resuspended in lysis buffer (see Chapter
II). Counting the cells in this manner, we found there was still a statistically
significant increase in the amount of RUFY1 KD cells 96 hours after transfection
(Figure 4.6B). However, the difference between the average number of siCON
and PTPN23 KD cells at this time-point was diminished when compared to only
counting viable cells. This suggests that the RUFY1 KD cells grow faster than
PTPN23 KD and siCON cells, and that there are fewer dead cells in the RUFY1
KD dishes.
Next, we wanted to determine if the increased relative number of the
RUFY1 KD cells was driven by EGFR activity. To test this, we treated cells with
an EGFR small molecule inhibitor, AG1478. We repeated the counting and
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harvesting of viable and inviable cells, and in addition, treated the 72- and 96hour time-points with 1μM AG1478 for 24 hours prior to harvest. This
concentration has been previously reported to be effective for attenuating EGFR
activation [65]. Although these cells were not stimulated with any EGFR ligands,
it was a possibility that the loss of RUFY1 KD had an effect on EGFR signaling.
We found that AG1478 did not change the relative cell number in the RUFY1 KD
cells 96-hours after transfection (Figure 4.6C).

PTPN23 loss and treatment with AG1478 leads to membrane blebbing
During the cell counting experiments, we monitored the morphology of the
cells at each time-point prior to harvest. Because there were less dead cells in
the RUFY1 KD dishes as compared to siCON control, we wanted to visualize any
potential morphological changes that might have been occurring in these cells.
We noticed that there were not any obvious changes in the morphology of the
RUFY1 KD cells (Figure 4.7B).
We also took images of the cells treated for 24-hours with the EGFR
inhibitor AG1478. Although this drug did not block the enhanced growth effect in
the RUFY1 KD cells, we did notice that, at the 96-hour time-point, there
appeared to be membrane blebbing in the PTPN23 KD cells treated with AG1478
(Figure 4.7C, inset). Though not quantified, this effect was seen in a multitude of
cells on the dish, and in all three replicates of the experiment.

Loss of RUFY1 reduces apoptosis, and loss of PTPN23 enhances apoptosis in
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Figure 4.7 Cell morphology of HeLa cells transfected with siCON, RUFY1,
and PTPN23 siRNA, and treated with AG1478. HeLa cells were transfected
with the indicated siRNA for 24-hours and replated at a density of 100,000
cells/35mm dish. Cells were then grown for the indicated period of time and
imaged at 100x magnification on a Nikon Eclipse Ti widefield epifluorescence
microscope. Cells treated with an EGFR-inhibitor were incubated with 1μM
AG1478 for 24-hours prior to imaging. Scale bar=50μm. Images are
representative of three independent experiments.
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HeLa cells
Due to the decreased number of dead cells in the RUFY1 KD cells and the
membrane blebbing seen in the PTPN23 KD cells, we wanted to determine if
there were any changes in cell death pathways occurring in these cell lines. We
chose to monitor PARP cleavage via immunoblotting. PARP cleavage is a
commonly used marker for apoptosis induction. After siRNA transfection, cells
were harvested and lysates were resolved on a 7.5% SDS-PAGE and
immunoblotted for PARP and α-tubulin. Quantification of the immunoblots by
Image J software showed a statistically significant decrease in PARP cleavage in
the RUFY1 KD cells as compared to siCON control (Figure 4.8). Conversely,
there was a significant increase in PARP cleavage in the PTPN23 KD cells 96hours after transfection (Figure 4.8). These results suggest that there is
decreased apoptosis induction in RUFY1 KD cells, and increased apoptosis
induction in PTPN23 KD cells.

Cell viability in RUFY1 KD and PTPN23 KD cells under various conditions
Finally, we set out to corroborate these findings with another assay, this
time monitoring cell viability using the alamarBlue assay. Due to distinct
differences in PARP cleavage and cell number seen at the 72- and 96-hour timepoints previously, we monitored the viability of knock-down cells at both timepoints. In addition, we treated the cells with varying concentrations of EGF ligand
or AG1478 EGFR inhibitor for 24 hours to determine if these had any effect on
cell viability. The 1mM AG1478 concentration was used as a positive
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Figure 4.8 PARP-cleavage induction in RUFY1 KD and PTPN23 KD cells.
HeLa cells were transfected with 50nM siRNA for 72- and 96-hours and
harvested to collect viable and inviable cells (see Chapter II). A. Lysates were
resolved on a 7.5% SDS-PAGE and immunoblotted for PARP and α-tubulin.
Immunoblots shown are representative of the 96-hour time-point from three
independent experiments. B. Immunoblots were quantified using Image J
software. The mean ± the standard deviation are plotted from three independent
experiments. PARP cleavage was calculated by dividing the quantification from
the bottom band in the immunoblot, and dividing it by the sum of the top and
bottom bands (cleaved PARP/total PARP).
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Figure 4.9 Cell viability in siCON, RUFY1 KD, and PTPN23 KD cells under
various conditions. HeLa cells were transfected with the indicated siRNA for 24
hours and then plated into 96-well dishes. After 24 hours of growth, the cells
were serum-starved for two hours, followed by 24 hours of incubation with either
10ng/mL EGF, 100ng/mL EGF, 1μM AG1478, or 1mM AG1478. The cells were
then incubated with alamarBlue reagent for two hours and the fluorescence was
read on a plate reader. The average of six replicates was taken and normalized
to the serum-starved control. The data plotted as the mean ± the standard
deviation (n=3). A. Cell viability 72-hours after knock-down. B. Cell viability 96hours after knock-down.
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control for cell death.
We found that EGF ligand stimulation did not increase cell viability, but
significantly decreased viability in PTPN23 KD cells at 72-hours (Figure 4.9A).
1μM concentration of AG1478 also decreased cell viability in PTPN23 KD cells at
this time-point. However, the effect was not seen at the 96-hour time-point.
RUFY1 KD cells showed a significant increase in cell viability after treatment with
1μM AG1478 at the 96-hour time-point (Figure 4.9B). This supports the claim
that RUFY1 KD cells appear to have a reduced susceptibility to cell death
processes, as this treatment reduced cell viability in siCON and PTPN23 KD
cells.

C. Discussion
The LC-MS/MS analysis of the isolated endosomes revealed that EGFR,
PTPN23, and three previously uncharacterized proteins (i.e. STOML2, RUFY1,
and CCDC51) associate with early endosomes in an EGF-dependent manner.
Unfortunately, there are no antibodies commercially available for the
uncharacterized coiled-coiled domain containing protein CCDC51, so we
restricted further studies to RUFY1, PTPN23 and STOML2. The temporal and
spatial association with the EGFR-containing endosomes could reflect an
important role for these proteins in regulating EGFR signaling.
We were struck by the absence of effector proteins among those
associated with the early endosome (ftp://massive.ucsd.edu/MSV000081692)
−more specifically, those that had been previously reported to be associated with
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EGFR containing endosomes (e.g. Shc, Grb2, MEK2, etc.) [30, 57, 69]. As such,
we wondered why these proteins were not detected in the mass spectrometry
analyses. Despite LC-MS/MS being a more sensitive detection method, it does
have limitations. As mentioned above, low-affinity associations with the
endosomes may have dissociated during the isolation procedure. Previous work
showing an association of these scaffold and effector proteins with early
endosomes used immunofluorescence and immunoblotting. An alternative
explanation is that the antibodies in those immune-detection methods generate
an amplification of a signal, whereas LC-MS/MS quantifies only the total number
of peptides present in a sample. As such, it is possible that the quantities of
these and other effector proteins in the early endosomes were too low to be
detected by LC-MS/MS; but, sufficient for detection via immunoblot and
immunofluorescence due to signal amplification.
RUFY1 has been previously reported to have a role in receptor tyrosine
kinase signaling; loss of RUFY1 has been shown to inhibit PDGF-induced
migration of fibroblasts [115]. These data support what other investigators have
found—that RUFY1 colocalizes with EEA1 [90, 96, 115] (Figure 4.3A). PTPN23
is the only of the four identified proteins to have been well studied in the context
of EGFR signaling and trafficking. PTPN23 acts as a coordinator of the ESCRT
complex pathway to transport internalized EGFR into multivesicular bodies [107,
114]. These data support the involvement of PTPN23 in EGFR endocytic
trafficking (Figure 4.3C). The third protein, STOML2, has been studied
exclusively in mitochondria. The literature contains numerous clinical reports of
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STOML2 being a driver of proliferation in multiple cancer types and is associated
with poor patient prognosis [109-111, 116]. Yet, the mechanism of STOML2 in
cancer cell proliferation remains unknown and the association of STOML2 with
EGFR in early endosomes introduces some possibilities. Together, these
findings initiate some important questions: What are the roles of these proteins in
the early endosome? Are these proteins required for EGFR functions? Do they
impact membrane trafficking? Do they affect EGFR signaling?
Of the three proteins, only STOML2 increases its colocalization with EEA1
with EGF treatment using immunofluorescence assays (Figure 4.3B). Although
this association is modest, it is consistent with a model in which the liganded
EGFR recruits STOML2 to the early endosome. This change in subcellular
location could permit novel interactions that drive new, previously unknown
functions of this protein. This is the first published result testing STOML2
fluorescence using the specified STOML2 antibody and it is worth noting that the
localization of the protein does not mirror what has been published using other
STOML2 antibodies [87]. This could be due to several possibilities: 1) STOML2
may have an abnormal distribution in HeLa cells, 2) STOML2 may be
overexpressed in HeLa cells and a large subgroup of the proteins are
mislocalized away from mitochondria and into endosomes, or 3) STOML2 has an
additional association with endosomes. Another protein in the STOML2 family,
SLP-1/STOML1, has been shown to localize to late endosomes [108], which is
consistent with STOML2 having a role in endocytic trafficking.
Biochemical and immunofluorescence analyses indicate that RUFY1 and
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PTPN23 colocalize with EEA1 independent of EGF treatment (Figure 4.3). This
observation contradicts the LC-MS/MS data that suggested an EGF-dependent
association of these proteins with early endosomes. One possible explanation for
this discrepancy is that the presence of active EGFR in early endosomes
increased the affinity of the candidate proteins with the compartment. As such,
the proteins may have dissociated from the endosomes during the biochemical
isolation protocol without EGF stimulation; trafficking of the receptor to the
endosomes stabilizes these proteins to the vesicles.
In an attempt to further elucidate their functional role in EGFR endocytic
trafficking, we used siRNA to knock down these proteins in HeLa cells. We
selected RUFY1 and PTPN23 for RNA silencing, because both RUFY1 and
PTPN23, but not STOML2, have previously reported endosomal functions. As
such, it is more plausible that their recruitment to the early endosome would
affect endocytic trafficking of EGFR.
Loss of either RUFY1 or PTPN23 slowed trafficking of the EGF:EGFR
complex and increased its colocalization with EEA1 (Figure 4.4). RUFY1 KD
yielded sustained EGF and EEA1 colocalization. This suggests that RUFY1 loss
slows the endocytic trafficking of the EGFR indicating RUFY1 enhances EGFR
trafficking. RUFY1 has been reported to play a role in early endosome transport
and recycling [86, 96] and these data support this role. PTPN23 KD yielded
sustained colocalization of EGFR with EEA1. This suggests that PTPN23 loss
resulted in the sequestration of the receptor in early endosomes upon EGF
stimulation. This is consistent with PTPN23 regulating EGFR trafficking toward

80

the late endosomes/lysosomal degradation. This aligns with the work of
Woodman and colleagues, who found that PTPN23 plays a critical role in MVB
morphogenesis and EGFR cargo sorting [85, 107].
We wanted to use an additional assay to monitor changes in EGFR
trafficking upon RUFY1 and PTPN23 KD. We chose to monitor radioligand
degradation, as these assays are extremely sensitive and highly repeatable.
While immunofluorescence allowed us to monitor the subcellular localization of
EGFR in the KD cells, using radio-labeled ligand allowed us to quantify changes
in ligand:receptor complex degradation. There was a significant decrease in both
radioligand degradation inside the cells, and secretion of ligand into the media in
PTPN23 KD cells (Figure 4.5). This supports previous findings that PTPN23 loss
slows EGF:EGFR trafficking to lysosomes and thus, degradation. Though the
immunofluorescence data showed an increase in EGF colocalization with EEA1
in RUFY1 KD cells, the radioligand assay did not show any changes in EGF
degradation or secretion as compared to siCON control. Taken together, these
data suggest that RUFY1 loss does not contribute to changes in EGFR
trafficking.
While propagating the RUFY1 KD HeLa cells, we noticed an increase in
their growth rate. We used cell counting methods to quantify this change, and
found a statistically significant increase in the number of RUFY1 KD cells (Figure
4.6). Other researchers have also used RNAi to knock down RUFY1 in various
cell lines, and have seen various effects. Vukmirica et al. knocked down RUFY1
in NIH 3T3 fibroblasts, and monitored cell migration. They reported that these
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cells exhibited decreased migration in response to PDGF-stimulation, as well as
a decrease in basal migration rates without ligand stimulation [115]. While
migration and cell growth are unique processes, it is still surprising that RUFY1
KD enhances cell growth or survival in one cell line, but stunts migration in
another. In a separate study, Ivan et al. knocked down RUFY1 in HEK293T cells,
and detected a 40% increase in plasma membrane protrusions as compared to
controls [97]. We monitored the morphology of RUFY1 KD HeLa cells, but did not
notice any changes in plasma membrane protrusions (Figure 4.7B). One
explanation for these discrepancies is the use of different cell lines. Regardless,
the loss of RUFY1 in HeLa cells lead to a dramatic increase in cell growth, and
we wanted to uncover the mechanism of this effect.
Naturally, we hypothesized that the increase in cell growth after RUFY1
loss could have been a result of changes in EGFR activity. Although the
trafficking of EGFR in these cells did not appear to be altered, it was possible
that the activity of EGFR was changed in some way. Because EGFR activity is a
known driver of cell proliferation, and we found an association of RUFY1 with
EGFR-containing early endosomes, this seemed to be a reasonable hypothesis.
We initially used biochemical techniques to monitor EGFR phosphorylation in the
knock-down cell lines, but the results were inconclusive (data not shown). As
such, we decided to use a chemical inhibitor of EGFR activity, AG1478. If EGFR
activity was driving cell survival or growth in HeLa cells that lacked RUFY1,
AG1478 would block this effect. However, we found that AG1478 did not
decrease the relative cell number of these cells (Figure 4.6C). In addition, we
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monitored viability of the RUFY1 KD cells after being treated with AG1478 for 24
hours, and these cells had increased viability when compared to siCON control
treated cells (Figure 4.9B). These data strongly suggested that the increased
cell numbers seen after RUFY1 loss in HeLa cells was not driven by EGFR
activity.
PTPN23 loss did not lead to the same increased relative cell number
effect as RUFY1 loss in HeLa cells. However, we did notice that AG1478
treatment at later time-points induced noticeable membrane blebbing in PTPN23
KD cells, but not in other cell lines (Figure 4.7C). Membrane blebbing is
generally attributed to the induction of apoptosis, or programmed cell death [117].
To quantify apoptosis induction in the KD cell lines, we monitored Poly ADPribose polymerase (PARP) cleavage in each knock-down cell line. PARP is a
family of proteins that are involved in DNA-repair. When a cell has begun the
process of initiating apoptosis, various caspases are activated which cleave
proteins to inhibit cell processes [117]. Caspase-3 cleaves PARP proteins, and
the cleavage of PARP proteins can be quantified via immunoblotting. We found
that, over time, PTPN23 KD cells had increased PARP cleavage (Figure 4.8).
This effect was not monitored after AG1478 treatment, but was seen in untreated
PTPN23 KD cells. In addition, we monitored the viability of these cells after
treatment with EGF ligand or AG1478 and found that all treatments significantly
reduced cell viability of PTPN23 KD cells at the 72-hour time-point (Figure 4.9A).
These results suggest that PTPN23 KD cells have an increased sensitivity to cell
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death induction. The mechanism of this effect is unknown, and future studies are
required to elucidate the cause of this sensitivity.
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CHAPTER V
SUMMARY AND FUTURE DIRECTIONS
A. Restatement of Research Goals
The goal of this dissertation work was to better understand the
implications of EGFR spatial regulation on its interactions with downstream
signaling proteins. While EGFR trafficking is well understood, there is currently
no consensus in the field as to how endocytic trafficking spatially regulates EGFR
signaling. Identifying proteins that are recruited to early endosomes in an EGFdependent manner not only provides a platform for further study on mechanisms
and outcomes, it also provides a means for finding new potential targets for
mediating EGFR signaling cascades.

B. Summary of Findings
We have developed a rapid and reproducible technique to isolate early
endosomes from cultured cells. Biochemical techniques were used to validate
the isolation of a pure population of early endosomes with virtually no
contamination from other organelles. Morphological studies revealed that the
isolated vesicles had similar characteristics to early endosomes.
In addition to developing this isolation technique, we used it to analyze the
proteome of early endosomes. We have identified four proteins associating with
early endosomes in an EGF-dependent manner: RUFY1, PTPN23, CCDC51,
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and STOML2 [118]. Other studies have reported an association of RUFY1 and
PTPN23 with early endosomes [85, 86]. However, this is the first report of either
CCDC51 or STOML2 associating with early endosomes. We validated the
association of RUFY1, PTPN23, and STOML2 with early endosomes using
indirect immunofluorescence and immunoblotting.
Knock-down studies were utilized to determine the roles that RUFY1 and
PTPN23 played in EGFR trafficking. Immunofluorescence revealed that the loss
of PTPN23 lead to a prolonged association of EGFR with EEA1, a marker for
early endosomes. Radioligand binding studies confirmed this phenomenon. This
finding is consistent with the literature and supports the claim that PTPN23 is an
important component of cargo sorting from late endosomes to lysosomes for
degradation.
Though these knock-down studies did not reveal any changes in EGFR
trafficking due to RUFY1 KD, we did notice that these cells had a dramatically
increase number of cells. To quantify this, we counted cells and found a
significant increase in the number of RUFY1 KD cells when compared to siCON
cells plated at the same density. While other reports have knocked down RUFY1
in various cell lines, we are the first to report this characteristic.
We wanted to determine if the increased number of RUFY1 KD cells was
driven by EGFR activity. A chemical inhibitor of the EGFR kinase, AG1478, was
used to block EGFR activity while monitoring cell number. These studies did not
reveal any change in RUFY1 KD cell number−however, monitoring the
morphology of the cells under a microscope revealed that AG1478 treatment
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caused membrane blebbing in the PTPN23 KD cells. This suggests that loss of
PTPN23 may increase susceptibility to cell death processes.
To quantify the induction of apoptosis in each cell line, PARP cleavage
was calculated using immunoblotting. These studies revealed that RUFY1 KD
cells had a significant reduction in PARP cleavage as compared to siCON cells,
suggesting loss of RUFY1 caused increased cellular stress tolerance. In addition,
we found that PTPN23 KD induced an increase in PARP cleavage. This result
corroborated the morphological images showing membrane blebbing in PTPN23
KD cells after AG1478 treatment. While the loss of RUFY1 seems to enhance
cell survival, the loss of PTPN23 seems to have the opposite effect.
Finally, we used the alamarBlue assay to quantify cell viability in each
knock-down cell line. These studies supported the hypothesis that RUFY1 KD
cells had increased viability under stressful conditions, and PTPN23 KD cells had
decreased viability overall. Future studies will be critical in determining the
underlying mechanisms for these findings.

C. Significance of Findings
The endosome isolation technique developed here could be utilized by
many areas of research. This technique can be applied to the study of numerous
proteins, receptors, kinases, and signaling effectors. For researchers interested
in other organelles, this technique can be modified by changing what Percoll
fractions are collected and what antigen is targeted during the affinity purification
step. The implications of application and adaptation of this isolation procedure for
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further research are vast.
Aside from the development of the isolation technique, the discovery of an
association of CCDC51 and STOML2 with early endosomes is completely novel.
Neither of these proteins has been previously reported to associate with either
EGFR or early endosomes. This provides a platform for numerous future studies
to elucidate the mechanisms of these interactions. In addition, virtually nothing is
known about the function of the protein CCDC51. The finding that CCDC51
associates with EGFR and early endosomes could provide some insights into the
roles of this protein.
We have also found that RUFY1 loss leads to enhanced survival. To the
author’s knowledge, this is the first report of its kind. Until now, RUFY1 has been
studied exclusively for its roles in endocytic trafficking. The mechanism for the
enhanced survival activity of RUFY1 is currently unknown.
The findings reported within this dissertation are significant for several
reasons. First, the early endosome technique developed herein can be used to
study myriad endocytic proteins, including other receptors that are endocytosed.
The isolation technique can also be modified to isolate other intracellular
organelles. Second, we have discovered novel associations of both CCDC51 and
STOML2 with both EGFR and early endosomes. Finally, we have discovered a
potential role for RUFY1 as driver of cell survival or cell growth. These
discoveries will drive multiple fields forward toward better understanding of
organelles, receptor trafficking, and CCDC51, STOML2, and RUFY1 functions.
D. Strengths and Weaknesses
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i. Strengths
A major strength of this work is in its use of HeLa cells. This cell line
expresses EGFR at levels similar to what has been measured in normal human
epithelial tissues (~50,000 EGFRs per cell), allowing us to correlate findings in
these cells with the physiologic activity of EGFR. To this same end, physiologic/
low levels of EGF ligand were used to stimulate EGFR activation (10ng/mL). Low
concentrations of EGF ligand limit endocytosis of EGFR to the clathrin-mediated
type, which is the type of endocytosis that occurs in normal physiology. Further,
HeLa cells grow rapidly, permitting the generation of large populations of cells,
which was required for subsequent endosome enrichment.
We were able to isolate early endosomes without introducing exogenous
factors into the cells. While it is generally acceptable to use cell lines that have
been genetically altered to enhance detection and capture of the target protein of
interest, we were able to enrich early endosomes without the use of epitope
tagged proteins or transfection reagents. As a result of this, the isolated early
endosomes are physiologically relevant. The proteomics data obtained from
these compartments can thus be taken at face value, without concerns about
non-physiologic changes in their structure or function.
The proteomics method used in these studies is also a strength of this
work, because LC-MS/MS is a highly sensitive and robust technique. In addition,
it provides researchers with an unbiased platform for analyzing the protein
composition of a sample. Other techniques require a prerequisite knowledge
regarding what proteins to study. Here, we were able to target a highly organelle-
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specific protein, EEA1, and assess the entire proteome of the compartments
isolated with this antigen. This approach uncovered a large amount of data from
in vitro samples that were reproducible.

ii. Weaknesses
One of the few limitations of this work is that it was performed using
cultured cells. A major drawback to using tissue culture rather than animals is
that the results cannot be correlated to the organism level. Cultured monolayers
of cells lack the complex interplay of signaling that occurs within organisms and
even tissues. Tissue culture models are ideal for preliminary studies, however,
isolating early endosomes from an animal would provide a more physiologically
relevant analysis of EGFR signaling from these compartments.
Another weakness of this work is that all experiments were conducted
using HeLa cells. Although this cell line is useful and extremely common, it is
important to remember that these cells are a human cervical adenocarcinoma
line. Cancer cells tend to behave and function in different ways from nontransformed cells, and there may be changes in signaling pathways in this cell
line for which we have not accounted. For this reason, it is crucial that this work
be repeated in other cell lines to validate that the findings reported herein are not
specific to HeLa cells.

E. Future Directions
The findings reported in this dissertation provide numerous avenues for
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future research. We have uncovered novel associations of STOML2 and
CCDC51 with early endosomes and EGFR. Because this is the first report of
these associations for either protein, future work is needed to understand the
roles these proteins play in endocytic trafficking and potentially EGFR signaling.
Although there are currently no commercially available antibodies for CCDC51,
the production of these would be critical to study the subcellular localization and
functions of this protein. STOML2 KD studies would also be a useful start to
determining the role of STOML2 in EGFR trafficking and signaling.
While we began studying RUFY1 in the context of EGFR trafficking and
signaling, more work is needed to determine the exact role of RUFY1 in this
regard, as well as to uncover the newly discovered survival role of RUFY1. One
protein that may serve as an intermediate to these processes is Etk, also known
as BMX. As discussed briefly in Chapter IV, one group found that Etk is required
for proper early endosome localization of RUFY1 by phosphorylating the RUFY1
coiled-coil domains [90]. Their data suggested that Etk plays a role in the plasma
membrane localization of EGFR, which was reversed upon introduction of the
RUFY1 FYVE domain into cells. They concluded there is an interplay between
Etk, RUFY1, and EGFR.
The interplay of Etk, RUFY1, and EGFR provides a novel perspective for
the research presented in this dissertation, particularly in regard to the increased
cell number effect that is induced upon loss of RUFY1. For example, if Etk
enhances plasma membrane localization of EGFR, and RUFY1 inhibits this
effect, then the loss of RUFY1 in cells would likely permit Etk to increase basal
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EGFR plasma membrane localization. The Yang group also found that the
enhanced localization of EGFR at the plasma membrane by Etk caused an
increase in MAPK activity after EGF stimulation [90]. They hypothesized that the
tyrosine kinase Etk is downstream of the signaling protein PI3K. If this is true,
then RUFY1 acts as a negative regulator of PI3K activity by inhibiting some of
the activities of Etk, which supports the finding in this dissertation that RUFY1
enhances cell survival. The inverse of this would be that loss of RUFY1 permits
uninhibited Etk activity. This would explain why blocking EGFR activity did not
reverse the increased cell number effect seen in RUFY1 KD cells. Although PI3K
is technically downstream of EGFR, if Etk is downstream of PI3K, then removing
an Etk inhibitor would permit Etk activity without EGFR activation. However, this
would require the activity of some other Etk-activating protein, be it PI3K or
another protein (Figure 5.1). Elucidating the relationships between Etk, EGFR,
and RUFY1 will likely be critical in uncovering how RUFY1 acts as a driver of cell
growth or survival.
There are numerous publications demonstrating that Etk has oncogenic
activity. Several clinical groups have shown that Etk overexpression drives
cancer cell proliferation and chemoresistance, and that loss of Etk diminishes
these effects [119-122]. These claims support the hypothesis that if RUFY1 does
in fact inhibit Etk activity, then RUFY1 has enhanced cell survival or growth
effects. Yang and colleagues reported that there are two potential binding sites
for RUFY1 and Etk to interact with one another [90]. This supports the notion of
RUFY1 inhibition of Etk. Only one study has demonstrated this effect, and future
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Figure 5.1 A schematic representation of a signaling pathway permitting
Etk to drive cell survival rates in RUFY1 KD cells.
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studies will be crucial in validating this finding and determining any other effects
induced by RUFY1 and Etk interactions.
One study that will be critical for testing the enhanced cell survival
activities of RUFY1 is to measure Etk activity in RUFY1 KD cells. If Etk activity is
enhanced after RUFY1 loss, then this should be easily measured using
biochemical techniques. It is possible that Etk phosphorylation is not increased,
but instead the loss of RUFY1 may permit additional interactions of Etk with other
proteins. It will be important to determine not only where RUFY1 and Etk are
binding but how this interaction changes the activity of Etk, be it structurally or
catalytically. One means to measure this would be to isolate the two proteins and
visualize their interaction using X-ray crystallography. Mutating various sites on
both proteins and creating dominant negative mutants will also be a useful
means for determining what domains of the proteins are interacting and how
each domain affects the function of each protein. However, the enhanced
survival activity of RUFY1 may be independent of Etk activity. Testing this would
require a simple experiment where both RUFY1 and Etk are knocked down in
HeLa cells. If loss of Etk inhibits the enhanced growth of RUFY1 KD cells, then
Etk is very likely to be the driver of cell growth upon RUFY1 loss. If Etk loss does
not inhibit this effect, then there is some other process mediating the increased
survival of RUFY1 KD cells that would need to be further explored. It is also
possible that Etk KD introduces additional effects to the cells. Etk KD alone in
HeLa cells should also be tested to determine how Etk loss affects HeLa cell
growth. Then, one could also determine if the loss of both Etk and RUFY1 has a
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synergistic effect on enhancing cell growth or survival. These studies will be
important for understanding the relationship between Etk and RUFY1.
Another caveat of RUFY1 and Etk interactions is that Etk phosphorylation
of RUFY1 is required for early endosomal localization of RUFY1 [90]. This role
could also be due to Etk being downstream of PI3K and could explain why we
detected an EGF-dependent localization of RUFY1 with early endosomes in
Chapter III. In other words, EGFR activation induces activation of the PI3K
pathway, including Etk, which phosphorylates RUFY1 and induces its localization
to early endosomes. However, as addressed in Chapter IV, other reports have
shown that RUFY1 is predominantly localized to early endosomes [95]. One
means for determining the role of Etk in RUFY1 localization is to knock down Etk
and monitor the localization of RUFY1 using immunofluorescence. This would
determine if Etk is necessary for RUFY1 localization to early endosomes. This is
another important aspect of the relationship between Etk and RUFY1 that needs
to be elucidated to better understand their functions in endocytic trafficking.
Though not exhaustive, we have presented multiple avenues for future
work that will be critical for expanding upon the findings of this dissertation. The
functional role of CCDC51 has yet to be determined, in regard to early
endosomal trafficking and otherwise. The mitochondrial protein STOML2 has
unknown roles in EGFR trafficking and signaling as well as cancer cell
proliferation that have yet to be elucidated. Finally, the survival effect of RUFY1
reported herein is the first of its kind. The mechanism behind this effect could be
due to the activity of the protein Etk. A number of experiments have been
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proposed that will be critical in determining the role of Etk in this phenomenon, as
well as the role of Etk on EGFR trafficking.
The original goal of this research was focused on elucidating the effects of
spatial regulation on EGFR signaling. In the process of pursuing this question,
we have uncovered several new proteins as effectors of EGFR in early
endosomes. While several new avenues of research have been presented that
could drive entirely novel fields of work, these proteins may also be important
drivers in EGFR trafficking and signaling. Future work that is focused on
uncovering the roles of these proteins in this manner will be crucial factors in
driving the field’s understanding of EGFR spatial regulation, endocytic trafficking,
and mitogenic signaling.
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